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DRUG DESIGN
[1-4] 
 Drug design, often referred to as rational drug design or simply rational 
design, is the inventive process of finding new medications based on the 
knowledge of a biological target. The drug is most commonly an organic small 
molecule that activates or inhibits the function of a biomolecule such as a protein, 
which in turn results in a therapeutic benefit to the patient. In the most basic sense, 
drug design involves design of molecules that are complementary 
in shape and charge to the biomolecular target with which they interact and 
therefore will bind to it. Drug design for the knowledge of the three-dimensional 
structure of the biomolecular target is equant but not necessarily relies 
on computer modelling techniques. This type of modelling is sometimes referred 
to as computer-aided drug design.  
Drug design that relies on the knowledge of the three-dimensional 
structure of the biomolecular target known as structure-based drug design. In 
addition to small molecules, biopharmaceuticals and especially therapeutic 
antibodies are an increasingly important class of drugs and computational methods 
for improving the affinity, selectivity, and stability of these protein-based 
therapeutics have also been developed. The major aim is to find whether the given 
molecule bind to the target and causes pharmacological actions or not. 
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Fig.1: Flowchart of Drug Discovery 
The basic steps involved in CADD are: 
1. Hit identification using virtual screening (structure- or ligand-based 
 design) 
2. Hit-to-lead optimization of affinity and selectivity (structure-based 
 design, QSAR, etc.) 
3. Lead optimization of other pharmaceutical properties while 
 maintaining affinity. 
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Types of drug design 
 Ligand-based drug design 
 Structure-based drug design 
Ligand Based Drug Design (LBDD) 
 It is also known as indirect drug design. In the absence of the structural 
information of the target, ligand based method is used to know about inhibitors for 
the target receptor. Biologically active lead molecule is detected by using 
structural or topological similarity or pharmacophoric similarity properties. There 
are several criteria‟s for similarity comparisons such as structure as well as shape 
of individual fragment or electrostatic properties of the molecule. The generated 
lead molecules are ranked based on their similarity score or obtained by using 
different methods or algorithms. 
Structure-based drug design (SBDD) 
 Structure-based drug design (or direct drug design) relies on knowledge 
of the three dimensional structure of the biological target obtained through 
methods such as X-ray, crystallography or NMR spectroscopy. If an experimental 
structure of a target is not available, it may be possible to create a homology 
model of the target based on the experimental structure of a related protein. Using 
the structure of the biological target, candidate drugs that are predicted to bind 
with high affinity and selectivity to the target may be designed using interactive 
graphics and the intuition of a medicinal chemist. Alternatively various automated 
computational procedures may be used to suggest new drug candidates. 
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Fig.2: Structure Based Drug Design 
 Alternatively various automated computational procedures are used to 
suggest new drug candidates. Currently, use of SBDD has become a standard 
exercise as a part of drug discovery and development, both in academics and 
industry.  
Typically, the process involves 
1.  Selection and identification of the target.  
2.  Search for lead or lead identification.  
3.  Lead optimization.  
Drug target 
 Drug discovery process begins with the identification of a possible 
therapeutic target. The selected drug target must be a key molecule involved in a 
specific metabolic or cell signalling pathway that is known or believed to be 
related to a particular disease state.  
Introduction 
 
 
 
 
Department of Pharmaceutical Chemistry 5 
 
Important drug targets include:  
 Enzymes (inhibitor- reversible or irreversible)  
 Receptors (agonist or antagonist)  
 Nucleic acid inter collators or modifiers  
 Ion channels (blockers or openers)  
 Transporters (uptake inhibitors)  
 The 3D structure of the protein target is usually obtained by X-ray 
crystallography [crystal structures of different macromolecules are available from 
the Research Collaboratory for Structural Bioinformatics (RCSB) Protein 
Database], Nuclear Magnetic Resonance (NMR) or homology modelling from a 
previously determined structure. Various other parameters like temperature 
factors, Vander Waals interactions, hydrogen bonding etc., in the region of 
interest on the target should be evaluated. 
VIRTUAL SCREENING TECHNIQUES (VS)
 [5-7] 
 Virtual screening (VS) is a computational technique used in drug 
discovery to search libraries of small molecules in order to identify those 
structures which are most likely to bind to a drug target, typically 
a protein receptor or enzyme.  
 Virtual screening has been defined as the "automatically evaluating very 
large libraries of compounds" using computer programs. As this definition 
suggests, VS has largely been a numbers game focusing on how the 
enormous chemical space of over 10
60
 conceivable compounds can be filtered to a 
manageable number that can be synthesized, purchased and tested. Virtual 
screening has become an integral part of the drug discovery process.
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Methods  
 These are two broad categories of screening technique: Ligand-based and 
structure based VS 
Ligand-based virtual screening technique 
 It is further divided into ligand alignment, Pharmacophoric approach 
and machine learning algorithms. 
 In Ligand alignment, a single 3D structure of a biologically active ligand 
is used as a template by ligand alignment for the super positioning and scoring of 
other 3D molecular structures from chemical libraries with respect to similarity of 
their characteristics like shape, interaction possibilities or physicochemical 
properties. 
 In Pharmacophoric approach, by use of structurally diverse set of 
ligands that bind to the receptor, a coarse-grained 3D surrogate of receptor is 
generated in the pharmacophoric approach. These are usually done by calculating 
all of the possible superposition of predefined chemical groups which are 
recognized at the target binding site and are responsible for the biological activity. 
This pharmacophoric, serves as template for the selection of the molecules which 
fulfil the specified geometrical constraints in the VS queries. 
 Machine learning algorithms relays on QSARs which correlate 
biological data with molecular descriptors hence derives statistical models used to 
predict activity of novel compounds. Some of the examples of the machine 
learning techniques that are becoming popular tools of model building and VS are: 
self-organizing maps (SOM), Binary QSAR, k-nearest neighbor approach (kNN), 
aritificial neural network (ANN), etc. 
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Structure-based virtual screening technique
 [8, 9]
 
 In silico or virtual screening (VS) of large compound collections to 
identify a subset of compounds that contains relatively many hits against the 
target. The compounds that are virtually screened can stem from corporate or 
commercial compound collections, or from virtual compound libraries. If a three-
dimensional (3D) structure or model of the target is available, a commonly used 
technique is structure-based virtual screening (SBVS) 
 Structure-based virtual screening involves docking of candidate ligands 
into a protein target followed by applying a scoring function to estimate the 
likelihood that the ligand will bind to the protein with high affinity. 
SEARCHING AND POSE PREDICTION 
 Searching for the correct binding mode (pose prediction) of a molecule is 
typically carried out by performing a number of trials and keeping those poses that 
are energetically best. It involves finding the correct orientation and, as most 
ligand molecules are flexible, the correct conformation of the docked molecule. 
The decision to keep a trial pose is based on the computed ligand–receptor 
interaction energy (score) of that pose. To identify and rank-order many different 
poses of a molecule during the search in a reasonable time, several programs 
calculate a „dock score‟ (a crude score based on a simple energy function such as 
a force field with an electrostatic term and repulsive and attractive Van-der-Waals 
terms), which can be evaluated very rapidly during the docking process, while a 
more sophisticated function is used to calculate the final „affinity score‟ for that 
molecule. 
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SCORING OR AFFINITY PREDICTION 
 Many of the scoring functions fall into one of two main groups. One main 
group comprises knowledge-based scoring functions that are derived using 
statistics for the observed interatomic contact frequencies and/or distances in a 
large database of crystal structures of protein–ligand complexes. Several such 
potentials to predict binding affinity have been developed (e.g., PMF, DrugScore, 
SmoG, and Bleep) 
 The other main group contains scoring schemes based on physical 
interaction terms. These so-called energy component methods are based on the 
assumption that the change in free energy upon binding of a ligand to its target 
can be decomposed into a sum of individual contributions: 
ΔGbind = ΔGint + ΔGsolv + ΔGconf + ΔGmotion 
 The individual terms in this equation account for the main energetic 
contributions to the binding event, as follows: specific ligand–receptor 
interactions (ΔGint), the interactions of ligand and receptor with solvent (ΔGsolv), 
the conformational changes in the ligand and the receptor (ΔGconf) and the motions 
in the protein and the ligand during the complex formation (ΔGmotion). Many 
popular scoring functions have been derived this way (e.g., LUDI, ChemScore, 
Validate, GOLD score, PLP, FlexX score, ScreenScore, Autodock3). Various 
approaches to derive optimal coefficients for regression based scoring functions 
exist. Most of them aim to reproduce experimental binding affinities. 
Advantages 
 Time and cost reduction of screening process of millions of small 
 molecules, compared to HTS (High Through-put Screening). 
 There is no need for physically existing compounds to perform the 
 screening process, unlike HTS. 
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 A large number of docking programs and scoring functions 
 Different approaches of VS have been created for lead discovery 
 depending 
 Each time on the availability of experimental information (SBVS 
 Ligand-Based VS, Fragment-Based VS, etc.) 
Limitations 
 Many VS tools are applicable and successful to specific case studies 
 (based on the training set) and not in general cases. 
 Compounds being identified by HTS are usually more bioactive  than 
 compounds identified by VS. 
 Weakness in perfect inclusion of receptor structural flexibility and of water 
in docking computations due to computational-cost and high complexity of 
its modelling. 
 Scoring is still challenging in predicting accurately the correct binding 
pose and ranking of the compounds due to the difficulties in 
parameterizing the complexity of the ligand-receptor binding interactions 
and the approximations in calculating desolvation and entropic terms. 
 By using various methods described above, lead moiety is identified by 
using software‟s like iGEMDOCK v.2, AUTODOCK, DOCK etc. The 
molecules which are docked well will be superimposed on one another. The 
ligands which are not docked well will be in different places. This lead molecule 
is being subjected to docking to know the interaction between the protein of 
interest and the lead. A graphical-automatic drug discovery system, called 
iGEMDOCK v.2 is used for integrating docking, post-analysis, screening and 
visualization. To our best knowledge, iGEMDOCK v.2 is the first system which 
combines structure-based virtual screening and post-screening analysis. 
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 The lead molecule which is identified by virtual screening are taken for 
lead optimization by knowing ADME data and drug likeliness properties. 
ADME data
 [10] 
 The high-throughput screening in drug discovery for absorption, 
distribution, metabolism and excretion (ADME) properties has become the norm 
in the industry. Only a few years ago it was ADME properties that were attributed 
to more failure of drugs than efficacy or safety in the clinic trials. With the 
realization of new techniques and refinement of existing techniques better 
projections for the pharmacokinetic properties of compounds in humans are being 
made, shifting the drug failure attributes more to the safety and efficacy properties 
of drug candidates. There are tremendous numbers of tools available to discover 
scientists to screen compounds for optimization of ADME properties and selection 
of better candidates. However, the use of these tools has generally been to 
characterize these compounds rather than to select among them. This report 
discusses applications of the available ADME tools to better understand the 
clinical implication of these properties, and to optimize these properties. It also 
provides tracts for timing of studies with respect to the stage of the compound 
during discovery, by means of a discovery assay by stage (DABS) paradigm. The 
DABS provide the team with a rationale for the types of studies to be done during 
hit-to-lead, early and late lead optimization stages of discovery, as well as 
outlining the deliverables (objectives) at those stages. DABS has proven to be 
optimal for efficient utilization of resources and helped the discovery team to 
track the progress of compounds and projects. Various medium and high 
throughput in vitro ADME screens are therefore now in use. In addition, there is 
an increasing need for good tools for predicting these properties to serve two key 
aims first, at the design stage of new compounds and compound libraries so as to 
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reduce the risk of late-stage attrition; and second, to optimize the testing and 
screening by looking at only the most promising compounds. Various software‟s 
and servers are available; one such is pharma algorithm server. 
DRUG LIKELINESS
 [11,12] 
 Druglikeness is a qualitative concept used in drug design for how 
"druglike" a substance is with respect to factors like bioavailability. It is estimated 
from the molecular structure before the substance is even synthesized and tested. 
A druglike molecule has properties such as: 
 Solubility in both water and fat, as an orally administered drug needs to 
pass through the intestinal lining after it is consumed, be carried in 
aqueous blood and penetrate the lipid-based cell membrane to reach the 
inside of a cell. 
 Potency at the biological target. 
 Several scoring methods can be used to express druglikeness as a function 
of potency and physicochemical properties, for example ligand 
efficiency and lipophilic efficiency. 
 Since the drug is transported in aqueous media like blood and intracellular 
fluid, it has to be sufficiently water-soluble in the absolute sense (i.e. must 
have a minimum chemical solubility in order to be effective). Solubility in 
water can be estimated from the number of hydrogen bond donors vs. alkyl 
side chains in the molecule. 
 Molecular weight: the smaller the better, because diffusion is directly 
affected. The great majority of drugs on the market have molecular 
weights between 200 and 600 Daltons 
 A traditional method to evaluate drug likeness is to check compliance 
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of Lipinski's Rule of Five, which covers the numbers of hydrophilic 
groups, molecular weight and hydrophobicity. There are many online 
servers available for calculating druglikeness score, one such is 
molinspiration server. 
LIPINSKI’S RULE OF FIVE[13] 
 Lipinski's rule of five also known as the Pfizer's rule of  five or simply 
the  rule of five (RO5) is a rule of thumb to evaluate druglikeness or determine if 
a chemical compound with a certain pharmacological or biological activity  
has properties that would make it a likely orally active drug in humans. The rule 
was formulated by Christopher A. Lipinski in 1997, based on the observation  
that most orally administered drugs are relatively small and 
moderately lipophilic molecules. 
 Lipinski‟s rule says that, in general, an orally active drug has not more 
than one violation of the following criteria:  
 Not more than 5 hydrogen bond donors (sum of OHs and NHs)  
 Not more than 10 hydrogen bond acceptors (sum of Ns and Os)  
 Molecular weight not greater than 500 Daltons  
 An octanol-water partition coefficient, log P, not greater than 5. 
 Number of violations less than 5 
Improvements  
 To evaluate druglikeness in a better way, the rules have spawned many 
extensions by Ghose et al. in 1999.  
 log P : -0.4 to +5.6 range 
 Molecular refractivity : 40-130  
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 Molecular weight : 160-480  
 Number of atoms : 20-70  
 Polar surface area must not be greater than 140 Å. 
 Over the past decade Lipinski‟s profiling tool for drug likeness has led to 
further investigations by scientists to extend profiling tools to lead-like properties 
of compounds in the hope that a better starting point in early discovery can save 
time and cost. 
DOCKING
 [14, 15] 
 Docking entails predicting the protein-ligand complex structure and is 
followed by scoring in SBVS in order to rank the compounds. Docking programs 
utilize various methods of conformational search in order to explore the ligand 
conformational space; these are categorized as following: 
a)  Systematic methods, which place ligands in the predicted binding  site 
 after considering all degrees of freedom. 
b)  Random or stochastic torsional searches about rotatable bonds, such as 
Monte Carlo and genetic algorithms to “evolve” new low energy 
conformers. 
(c) Molecular Dynamics simulation methods and energy minimization for 
exploring the energy landscape of a molecule. 
 Molecular docking may be defined as an optimization program, which 
would describe the „best-fit‟ orientation of a ligand that binds to a particular 
protein of interest. The focus of molecular docking is to computationally stimulate 
the molecular recognition process.  
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Fig.3: Docking 
 The aim of molecular docking is to achieve an optimized conformation for 
both the protein and ligand and relative orientation between protein and ligand 
such that the free energy of the overall system is minimized.  
A molecular docking calculation consists of the following steps:  
 Optimization of the ligand geometry, calculation of pH-dependent  partial 
 charges, and identification of rotatable bonds.  
 Calculation of electrostatic properties of the protein of interest and 
 defining the ligand –binding region.  
 Calculation of ligand-protein interaction by a scoring function that 
 includes terms and equations that describe the intermolecular 
 energies. 
 Docking produces plausible candidate structures. These candidates must 
be ranked by using scoring functions and to identify structures that are most likely 
to occur in nature.  
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Rigid-body docking and flexible docking  
 If the bond angles, torsion angles and bond lengths of the components are 
not modified at any stage of complex generation, then they are known as rigid 
body docking. A rigid-body docking is sufficiently good for most docking, when 
substantial change occurs within the components at rigid-body docking. Docking 
procedures which permit flexible docking procedures or conformational change, 
must intelligently select small subset of possible conformational changes for 
consideration. 
Mechanics of docking  
 To perform a docking screen, the first requirement is a structure of 
interested protein. Usually the structure has been measured using a biophysical 
technique such as X-ray crystallography or NMR spectroscopy. The protein 
structure and a database of potential ligands serve as inputs to a docking program. 
The success of a docking program is based on two components:  
Search algorithm 
 The search space includes all possible orientations and conformations of 
the protein paired with ligand. With present computing resources, it is impossible 
to exhaustively explore the search space; which involves enumerating all possible 
distortions of each molecule (molecules are dynamic and exist in an ensemble of 
conformational states) and all possible rotational and translational orientations of 
ligand relative to the protein at a given level of granularity. Most docking 
programs account for a flexible ligand, and several are attempting to model a 
flexible protein receptor. Each “snapshot” of the pair is referred to as a pose.  
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 There are many conditions for sampling the search space. Here are some 
examples:  
 Use a coarse-grained molecular dynamics simulation to propose 
energetically reasonable poses stimulation. (direct search-simplex method; 
gradient-based search-steepest descent, Fletcher-Reeves method, Newton-
Raphson method; least square methods-Marquardt method)  
 Simulated annealing (Monte Carlo search of the parameter space)  
 Use a “linear combination” multiple structures determined for the  same 
 protein to emulate receptor flexibility  
 Use a genetic algorithm to “evolve” new poses that are successively 
 more fragment-based construction.  
Scoring function 
 The scoring function takes a pose as input, returns a number indicating the 
likelihood that the pose represents the favourable binding interaction.  
 Most scoring functions are physics based molecular mechanics force fields 
that estimate the energy of the pose; a low (negative) energy indicates a stable 
system and thus likely for a binding interaction. It is an alternative approach to 
derive a statistical potential for interactions from a large database of protein-
ligand complexes, such as the Protein Data Bank. This evaluates the fit of the pose 
according to this inferred potential.  
 There are a large number of structures from X-ray crystallography for 
complexes between proteins and high affinity ligands. It is comparatively fewer 
for low affinity ligands as the later complexes tend to be less stable and therefore 
more difficult to crystallize. Scoring function trained with this data can dock hits 
(ligands predicted to bind to the protein and actually do not, when placed together 
in a test tube). 
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Autodock 4.2 
 Autodock is a suite of automated docking tools. It is designed to predict 
how small molecules, such as substrates or drug candidates, bind to a receptor of 
known 3D structure. Autodock uses Monte Carlo method and simulated annealing 
in combination with genetic algorithm for building the possible conformations. 
The genetic algorithm is used for global optimization. Autodock works in Linux 
platform. Cygwin is used as a user friendly interface. The local search method is 
energy minimization and Amber “force field” model helps in the evaluation of 
binding positions compatible with several scoring functions based on the free 
energy. The atomic affinity grids can be visualized. This is helpful to guide 
organic synthetic chemists to design better binders. Autodock consists of two 
main programs:  
 AutoGrid pre-calculates the grids.  
 AutoDock perform the docking of the ligand to a set of grids 
 describing the target protein.  
 It also has got capabilities to visualize atomic affinity grids and its 
graphical user interface, thus to support the analysis of docking results. It has an 
advantage of getting free academic license, at the same time parallel computation 
is not supported.  
ANTIMALARIAL AGENTS
 [16,17] 
 Antimalarial agents are chemotherapeutic agents which are used for the 
prevention and treatment of malaria. Malaria is a mosquito-borne infectious 
disease affecting humans and other animals caused by parasitic protozoans (a 
group of single-celled microorganisms) belonging to the Plasmodium type. The 
disease is most commonly transmitted by an infected female Anopheles mosquito. 
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The mosquito bite introduces the parasites from the mosquito's saliva into a 
person's blood. The parasites travel to the liver where they mature and reproduce. 
Five species of Plasmodium can infect and be spread by humans. Most deaths are 
caused by P. falciparum because P. vivax, P. ovale, and P. malariae generally 
cause a milder form of malaria. The species P. knowlesi rarely causes disease in 
humans. Malaria is typically diagnosed by the microscopic examination of blood 
using blood films, or with antigen-based rapid diagnostic tests. Methods that use 
the polymerise chain reaction to detect the parasite's DNA have been developed, 
but are not widely used in areas where malaria is common due to their cost and 
complexity. 
LIFE CYCLE 
 In the life cycle of Plasmodium, a female Anopheles mosquito (the 
definitive host) transmits a motile infective form (called the sporozoite) to a 
vertebrate host such as a human (the secondary host), thus acting as a transmission 
vector. A sporozoite travels through the blood vessels to liver cells (hepatocytes), 
where it reproduces asexually (tissue schizogony), producing thousands of 
merozoites. These infect new red blood cells and initiate a series of asexual 
multiplication cycles (blood schizogony) that produce 8 to 24 new infective 
merozoites, at which point the cells burst and the infective cycle begins anew.  
 Other merozoites develop into immature gametocytes, which are the 
precursors of male and female gametes. When a fertilized mosquito bites an 
infected person, gametocytes are taken up with the blood and mature in the 
mosquito gut. The male and female gametocytes fuse and form an ookinete a 
fertilized, motile zygote. Ookinetes develop into new sporozoites that migrate to 
the insect's salivary glands, ready to infect a new vertebrate host. The sporozoites 
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are injected into the skin, in the saliva, when the mosquito takes a subsequent 
blood meal. 
Only female mosquitoes feed on blood; male mosquitoes feed on plant 
nectar and do not transmit the disease. The females of the Anophelesgenus of 
mosquito prefer to feed at night. They usually start searching for a meal at dusk 
and will continue throughout the night until taking a meal. Malaria parasites can 
also be transmitted by blood transfusions, although this is rare. 
 
 
Fig.4: Life Cycle of Malarial Parasite 
Classification of Antimalarial drugs
[18] 
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4-Aminoquinolines 
Chloroquine (CQ), Amodiaquine (AQ), 
Piperaquine 
Quinoline-methanol Mefloquine 
Acridine Mepacrine 
Cinchona alkaloid Quinine, Quinidine 
Biguanides Proguanil(Chloroguanide) 
Diaminopyrimidines Pyrimethamine 
8-Aminoquinoline Primaquine, Tafenoquine, Bulaquine 
Sulfonamides and Sulfone 
Sulfadoxine, Sulfamethopyrazine 
Dapsone 
Anitibiotics Tetracycline,Doxycycline, Clindamycin 
Sesquiterpine lactones Artesunate, Artemether, Arteether 
Phenanthrene methanol Halofantrine 
Naphthoquinone Atovaquone 
 
Pharmacological classification of Anti-Malarial drugs 
Classification Stages Drugs 
Blood schizonticidal 
drugs 
Erythrocytic phase 
Chloroquine, Artemissin. 
Quinine, Atovaquone 
Tissue schizonticidal 
drugs 
Tissue form of 
plasmodium 
Primaquine, 
Pyrimethamine, 
Proguanil, Tetracycline 
Gametocidal drugs 
Destroy sexual forms of 
parasite prevent 
transmission to 
mosquitoes 
Primaquine, Quinine 
Hypnozoiticidal 
Destroy persistent liver 
stage of P.Vivax, P. 
ovale 
Primaquine 
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Fig.5: The Site of action of Antimalarial drugs 
Plasmodium Falciparum Enoyl-acyl carrier protein Reductase (PfENR)
[19-22] 
 Fatty acids plays a critical role in providing metabolic precursors of 
biological membranes and also  represent an important form of metabolic energy, 
making their biosynthetic pathway an excellent target for antimicrobial agents. 
The fatty-acid biosynthesis pathway is localized in the parasite apicoplast, an 
essential organelle ancestrally related to cyanobacteria. In brief, the fatty acid 
synthesis starts with the formation of malonyl-acyl carrier protein (ACP) by 
malonyl-CoA ACP transacylase (MAT). Malonyl-ACP undergoes 
decarboxylative condensation with acetyl-CoA by the enzyme β-ketoacyl-ACP 
synthase III (KS) or acyl-malonyl-ACP condensing enzyme (FabB or FabF), 
respectively. This reaction is followed by nicotinamide adenine dinucleotide 
phosphate reduced (NADPH) dependent reduction, which is catalyzed by β -
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ketoacyl-ACP reductase (KR) forming β-hydroxy butyryl-ACP. β-Hydroxy 
butyryl- ACP is then dehydrated to trans-2-butyryl-ACP (crotonoyl- ACP) by 3-
hydroxy acyl-ACP dehydratases (DH). 
 The last step is the nicotinamide adenine dinuleotide reduced (NADH) 
dependent reduction, of the enoyl-ACP catalyzed by enoyl-ACP reductase (FabI) 
forming butyryl-ACP. Repetition of the elongation cycle 6–7 times yields a long 
acyl chain covalently linked to ACP. Plasmodium enoyl-ACP reductase (PfENR) 
catalyses the deterministic step of the elongation cycle and therefore, has emerged 
as an important drug target. 
 
Fig.6: Pathway for fatty acid synthesis 
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 Abbreviations are as follows: acyl carrier protein (ACP), malonyl 
transferase (MAT), β-ketoacyl acyl carrier protein reductase (KR), 3-hydroxyacyl 
ACP dehydrase (DH), enoyl-acyl carrier protein reductase (ENR), β-ketoacyl acyl 
carrier protein synthetase (KS), and coenzyme A (CoA). 
 The substrate-binding loops
 
of PfENR have a maximum number of 
interactions with NAD
+
 and they have the best binding affinities with triclosan 
with inhibition constants in the picomolar range. Triclosan binds non-covalently 
in this loop such that the ether linkage of triclosan is oriented like the enoyl group 
of the fatty acyl substrate. The ring A of triclosan nestles in a hydrophobic pocket 
lined by the residues, Tyr267, Tyr277, Gly313, Pro314, Ile323, Phe368, Ile369, 
and Ala372, while ring B of triclosan is surrounded by the nicotinamide ribose 
and the phosphates of NAD
+
, Met281 and the substrate-binding loop residues 
Ala319, Ala320, and Ile323 and another loop with conserved residues Ala217, 
Asn218, Ala219, and Val222.14 While the interactions between the substrate-
binding loop of the protein and NAD
+
 dictate, to an extent, the affinity of the 
protein for triclosan, there are direct interactions, too, between ENR and triclosan. 
The phenolic OH of triclosan makes hydrogen bonds with NO
+
2 of nicotinamide 
ribose and with Tyr277 OH in PfENR which are conserved in other pathogenic 
organisms too, thus making it very critical for the inhibitory activity. Therefore, 
the most suitable positions for enhancing the biological activity of diphenyl ether 
class of compounds can be the substitutions at position 4 in ring A and position 20 
and 40 in ring B. Examination of the PfENR:NAD
+
 triclosan structure has earlier 
revealed that the 40 chloro group is in vanderwaals contact with the hydrophobic 
sidechains of Val-222 and Met-281. The halogen is directed toward the sidechain 
of Asn-218 and the backbone carbonyl of Ala-219, and is approximately 4 A˚ 
from the solvent accessible surface, therefore the 40-position could serve to 
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append functionality to alter the physiochemical properties of the inhibitor. 16 The 
20-chloro group, on the other hand, is in close proximity to Ala-217 and atoms of 
the pyrophosphate moiety of NAD+. So the inhibitory activity against PfENR 
Series of pyrazolyl linked thiazolidinone, oxazepine and benzoxazepine was 
determined. 
ANTIBACTERIAL AGENTS
 [25-29] 
 Bacteria are unicellular organisms. Under a microscope, they look like 
balls, rods or spirals. Some bacteria help to digest food, give the needed vitamins 
for body and destroy disease-causing cells. Bacteria are used in making healthy 
foods like yogurt and cheese. 
 But infectious bacteria can cause infections. They reproduce quickly in 
body. Many produce chemicals called toxins, which damages tissue and make you 
sick. Examples of infections causing bacteria include Escherichia coli, 
Streptococcus and Staphylococcus. 
Bacteria role in disease 
 Most E.coli strains do not cause disease, but virulent strains can cause 
gastroenteritis, urinary tract infections, neonatal meningitis, hemorrhagic colitis, 
and Crohn's disease. In rarer cases, virulent strains are also responsible for bowel 
necrosis (tissue death) and perforation without progressing to hemolytic-uremic 
syndrome, peritonitis, mastitis, septicemia, and gram-negative pneumonia. There 
is one strain, E. coli 0157:H7 that produces the Shiga toxin (classified as a 
bioterrorism agent). This toxin causes premature destruction of the red blood cells, 
which then clog the body's filtering system, the kidneys, causing Hemolytic-
Uremic Syndrome (HUS). Uropathogenic E.coli (UPEC) is one of the main causes 
of urinary tract infections. Certain strains of E.coli are a major cause of foodborne 
Introduction 
 
 
 
 
Department of Pharmaceutical Chemistry 25 
 
illness. The outbreak started when several people in Germany were infected with 
enterohemorrhagic E.coli (EHEC) bacteria, leading to hemolytic-uremic 
syndrome (HUS), a medical emergency that requires urgent treatment. 
Antibacterial drugs 
 Antibacterial agents are agents that are „selectively‟ toxic to bacteria, 
either killing them (bactericidal) or inhibiting their growth (bacteriostatic) without 
causing harm to the patient. These compounds act on structure found in bacteria 
and not in the host. 
 Antibacterial agents may be either antibiotics, which are natural substances 
produced by certain groups of microorganism or chemotherapeutic agents which 
are chemically synthesized. A semi synthetic antibiotic produced by the chemist 
by chemically modifying a molecular version, produced by the microorganism to 
impart desired properties. 
Antibacterial agents specific to E.coli 
 Amoxicillin along with other semi-synthetic penicillins 
 Cephalosporins 
 Carbapenems 
 Aztreonam 
 Trimethoprim-sulfamethoxazole 
 Ciprofloxacin 
 Nitrofurantoin 
 Aminoglycosides 
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Fig 7: The site of action of Antibacterial drugs 
Escherichia coli Enoyl-acyl carrier reductase protein Reductase (E.coli FabI)  
 Owing to the development of new antibacterial agents which are non-
resistant and site active, the enzyme inhibitory drug targets have been the main 
focus for the researchers. Enzymes that compromise the fatty acid synthetase 
(FAS) complex responsible for fatty acid biosynthesis are considered ideal targets 
for designing new antibacterial agents. Enoyl ACP reductase is a key regulatory in 
fatty acid elongation. Virtual screening and the databases revealed the importance 
of triclosan based E.coli- ENR inhibitors which act as the antibacterial agents by 
inhibiting the enoyl ACP reductase (ENR) enzymes. 
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The fatty acid synthase system of Escherichia coli is the paradigm for the 
type II or dissociated fatty acid synthase systems. Distinct genes encode each of 
the individual enzymes, and the same basic chemical reaction is often catalysed by 
multiple isozymes. There are four basic reactions that constitute a single round of 
elongation. The first step is the condensation of malonyl-ACP with either acetyl-
CoA to initiate fatty acid synthesis (FabH) or with the growing acyl chain to 
continue cycles of elongation malonyl-ACP (FabB or FabF). The β-ketoacyl-ACP 
(FabH) is reduced by an NADPH-dependent β-ketoacyl-ACP reductase (FabG). 
There are two β-hydroxyacyl-ACP dehydratases (FabA or FabZ) capable of 
forming trans-2-enoyl-ACP. The product of the FabA gene is specifically 
involved in the introduction of a cis double bond into the growing acyl chain at 
the β-hydroxydecanoyl-ACP step and most efficiently catalyzes dehydration of 
short-chain β-hydroxyacyl-ACPs, whereas the FabZ dehydratase has a broader 
substrate specificity. The last reaction in each elongation cycle is catalysed by 
enoyl-ACP reductase (FabI). 
 
Fig.8: Biosynthetic pathway for fatty acid synthesis 
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 Reviews reveal that the main chains of Gly93–Ala95 involve vander 
Waals contacts with the bound NAD
+
. Hydrophobic interaction with Leu100, 
Tyr156, Met159, Ala196 and Ile200 and a couple of water molecules are been 
observed in the binding domain Gly 93, Ala 95, Tyr 146, Pro 191, Ile192, Tyr 
194, Ala 196, Ala197, Phe 203and Met 206 forms the binding pocket. 
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LITERATURE REVIEW 
2.1  PYRAZOLE 
 Nisheet et al., synthesized N-substituted thiazolidinone containing 
pyrazole(1) and screened for antimicrobial activity against Escherichia 
coli, Staphylococcus aureus, Pseudomonas aeruginosa.
 [30]
 
N
N
S
N
N
O
O
R
 
 (1) 
 Pawar et al., synthesized some pyrazole, thiazolidinone derivatives (2) and 
 the compounds were screened for their antibacterial activity.
 [31]
 
O
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 Sah et al., reported the synthesis of substituted pyrazoles bearing 2-aryl 
amino -5- mercepto-1, 3, 4- thiadiazole (3) nuclei as possible antimicrobial 
agents.
 [32]
 
NH N
S
N
S
O2N
N
O
N
CH3
CH3
R1
R
1
=H,Cl
 
(1) 
 Garkwad et al., synthesised certain N-1-[2-hydroxy benzoyl]- 5 –
substituted phenyl-3- phenyl 4,5- dihydro pyrazoles (4) and screened for 
their antimicrobial activity.
 [33]
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(2) 
 Vijaykumar et al., synthesised novel 1,5-diaryl pyrazole (5) derivatives 
 which exhibited good antibacterial and antifungal activities.
 [34]
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 Garg et al., synthesised 1-thiocarbonyl 3-trifluoro methyl-5- phenyl-4(2-
fluro phenyl azo) pyrazoles (6). These compounds showed significant 
antibacterial activity against S.aureus, S.typhi and E.coli.
 [35]
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(4) 
 Mistry et al., succeeded in the synthesis of a series of pyrazolo (5,4-d) – 
 pyrimidine (7) derivatives which exhibited antimicrobial activity.
 [36]
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(5) 
 Bhawsar et al., synthesised some new coumarino pyrazoles (8) and were 
 evaluated them for antimicrobial activity.
 [37]
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 Faidallah et al., synthesised 3,5-disubstituted pyrazoles (9)from chalcones. 
 Their antimicrobial activities have been examined successfully.
 [38]
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(7) 
 Vishnu et al., reported the synthesis of a few pyrazoles (10) and these 
 compounds were screened for antimalarial activity.
 [39]
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(8) 
 
 Bekhit et al., synthesized new heterocyclic hybrids of pyrazole and its 
 bioisosters(11).They were screened for antimalarial-antileishmanial 
 activity.
 [40]
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 Sanjay et al., synthesis of substituted pyrazole (12). They were screened 
for potential antimalarial target of the Enoyl-ACP Reductase inhibitor of 
Plasmodium falcipuram.
 [41]
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(10) 
 Sabine et al., synthesis of 4-[5-(4-Phenoxyphenyl)-2H-pyrazol-3-
 yl]morpholine (13) derivatives. They were screened for antiparasitic 
 activities.
 [42]
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2.2  THIAZOLIDINONE  
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 Nadia G.Kandile et al., synthesized of new schiff’s base bearing 
thiazolidine derivatives (14). They screened for antibacterial and 
cytotoxicity evaluation.
[43]
 
 
(12) 
 Zeki A.Naser AI- Shamkhani et al., synthesized some novel schiff’s base 
 thiazolidinone derived from mefenamic acid(15) possessing antibacterial 
 activity against antiEscherichia coli.
[44]
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(13) 
 Sayaji S.Didwagh et al., synthesized of novel thiazolidin-4-one (16) 
derivatives possessing antibacterial activity against Escherichia coli, 
Pseudomonas aeruginosa and Bacillus substilis.
 [45]
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(14) 
 Desai et al., synthesized novel Heterocyclic 4-thiazolidinone derivatives 
(17) and screened for their antibacterial activity against Escherichia coli 
and Staphylococcus aureus.
 [46]
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(15) 
 Pushkal samadhiya et al., synthesized 4-thiazolidinone derivatives (18) and 
 screened for antitubercular and antimicrobial activity.
 [47]
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(16) 
 Navin B.Patel et al., synthesized new 4-thiazolidinone derivatives (19) 
possessing antimicrobial activity against Escherichia coli and antifungal 
activity against candida albicans.
 [48]
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(17) 
 Mogilaiah et al., synthesized 4-thiazolidinone (20) and screened for their 
antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, 
and Bacillus substilis.
 [49]
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(18) 
 Bhoot et al., synthesized of 2-(p-tolylimino)-3-(4-tolyl)-5-(5’-(3,4-
dichlorophenyl))-thiazolidinone(21) possessing antimicrobial activity 
against Escherichia coli, Pseudomonas Vulgaris and antifungal agent 
against Aspergillus niger.
 [50]
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N
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R
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Cl  
(19) 
 Altintas et al., synthesized 5-substituted 5-(N,N-disubstituted 
aminomethyl)-2-[(4-carbethoxymethylthiazol-2-yl)imino]-4-
thiazolidinones (22) were screened for their in vitro antibacterial activity 
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against  Staphylococcus aureus, Escherichia coli, Klebsiella pneumonia, 
Pseudomonas aeruginosa, Salmonella typhi using disc diffusion method.
 
[51]
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(20) 
 Desai KG and Desai KR have synthesized 2-(aryl)-3-[2-
(benzothiazolylthio)-acetamidyl]-4-oxo-thiazolidines (23) the compounds 
have been screened for their antibacterial activity against Escherchia coli, 
Staphylococcus aureus and Bacillus substilis.
 [52]
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(21) 
 Saeed A etal., synthesized derivatives of 2-aroylimino-3- 
 arylthiazolidin-4-ones (24) and were screened for antimicrobial 
 activity.
 [53]
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(22) 
 Chawla et al., synthesized 2,5-disubstituted 4-thiazolidinone 
(25) analogues possessing antibacterial activity against Escherichia coli, 
Pseudomonas aeruginosa and antifungal against Candida albicans.
 [54]
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(23) 
 Tejaskumar et al., synthesized fluorinated 4-thiazolidinones (26) having 
antibacterial activity against Escherichia coli, Pseudomonas aureginosa, 
Bacillus substilis. They screened for their antifungal activity against 
Candida albican.
[55]
 
Literature Review 
 
 
 
 
Department of Pharmaceutical Chemistry 39 
N
N
NH
NH
N
S
O
R
OS
X
Cl
Cl F
 
(24) 
 Vicini et al., synthesized 2-thiazolylimino-5-benzylidene-4-thiazolidinones 
 (27) were screened for their antibacterial and antifungal activity.
 [56]
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(25) 
 A.P. Rajput et al., synthesized 2,5-dichloro-3,4-diformyl (N-substituted 
phenyl pyrroles thiazolidinones derivatives (28) were screened for their 
antibacterial activity.
 [57]
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 A.N. Solankee et al., synthesized 4-thiazolidinones (29) and were 
 screened for their antibacterial and antifungal activity.
 [58]
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(27) 
 Gyanendra et al., synthesis of 5-Benzylidene-2-thioxothiazolidin-4-one 
(30) Rhodanine class of compounds and were screened for PfENR enzyme 
inhibitors.
 [59]
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(28) 
 Raja et al., designed and synthesized some 4-aminoquinline-derived 
thiazolidines (31) and were screened for their antimalarial activity and 
heme polymerization inhibition studies.
 [60]
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 Agular et al., synthesized primaquine-thaizolidinones derivatives (32) 
 which possessing antimalarial activity.
 [61]
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(30) 
 F.A. Rojas Ruiz et al., synthesized and screened for antimalarial activity 
evaluation of new heterocyclic hybrids (33) based on chloroquine and 
thiazolidinone.
[62]
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(31) 
 Ashish bhatt et al., synthesized novel thiadiazole derivatives incorporating 
imidazo[1,2-b] pyridazine and thiazolidinone moieties (34) were 
possessing antimalarial and antibacterial activity.
 [63]
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 Varun A. Morde et al., synthesised of N-benzylidene-4-phenyl-1,3-thiazol-
2-amine (35)  biological evaluation of Plasmodium falciparum enoyl-acyl 
carrier protein reductase (PfENR) inhibitor.
[64]
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(33) 
 Rajni Kant Sharma et al., Synthesized and studied and studied SAR of 
thiazolidinone(36) as antiplasmodial inhibitor of the Plasmodium 
falciparum cysteine protease falcipain-2.
[65]
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2.3  OXAZEPINE AND BENZOXAZEPINE 
 Naruka al., synthesized formamidine disulfuide Schiff’s  base and their 
corresponding 1,3–oxazepine (37)and 2,4-benzoxazepine (38) possessing 
antibacterial activity against Escherichia coli, Staphylococcus aureus and 
antifungal activity against Aspergillus niger.
 [66]
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(37) (38) 
 
 Khitam T.A .Alsultani., synthesized oxazepine derived from schiff’s base 
(39) and screened for their antibacterial activity against Escherichia coli, 
Staphylococcus aureus and Bacillus substilis.
[67]
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 Hamak KF et al., synthesized benzoxazepine derivatives (40) from 
Schiff’s base and screened for their antibacterial activity against 
Escherichia coli, Bacillus substilis, Staphylococcus aureus and 
anticorrosion activity.
 [68]
 
O N
O O
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O
R
 
(40) 
 Ibrahim et al., synthesized schiff’s base derivatives of 1,3-oxazepine(41) 
and benzoxazepine (42) screened for antibacterial activity against 
Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa.
 [69]
 
O
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O
N
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O NH
O
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R  
(41)    (42) 
 Ahmed et al., synthesized some new oxazepine derivatives (43) possessing 
antibacterial activity against Escherichia coli, Bacillus substilis and 
Staphylococcus aureus.
 [70]
 
Literature Review 
 
 
 
 
Department of Pharmaceutical Chemistry 45 
O
N
O
O NH
O
NH2
Ar  
(43)  
 Anila et al., synthesized novel 5,6–Benz-1,3-oxazepine-4,7-dione(44) and 
1,3-oxazepine (45) derivatives and were screened for their antibacterial , 
antioxidant and anti-inflammatory activity.
 [71]
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(44)     (45) 
 Kendre et al., synthesized some novel pyrazole(46), benzoxazepine 
derivatives(47) and were screened for their antibacterial, antifungal and anti-
inflammatory activity.
[72]
 
OTs N N
R
Ph
O
OTs
O
N
CH3
O
 
(46)     (47) 
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 Muhsen et al., synthesized and characterized some novel compounds 
containing oxazepine rings (48) were screened for their antibacterial 
activity against E.coli , S.aureus and Bacillus cereus.
 [73]
 
O
N
+
O
O
N
H
S
O
CH3
CO2
 
(48) 
 
 Hawraa Mohammed sadiq., synthesized and characterized some Novel 
1,3-oxazepine (49) derivatives from aminopyrazine.
 [74]
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PURPOSE AND PLAN OF WORK
 
 The prime motivation of the present work is to design a drug in such a way 
that it can be used clinically to treat the disease. Drug discovery tools have been 
utilized now in designing new molecular entities which are safe and effective 
without consuming much of the research hours. Recent literatures shows that 
search of new drugs are now focussed on design of drugs as inhibitors of enzyme 
targets.  
Enoyl ACP reductase is such a potential drug target in the development of 
new antimicrobial agents. From the literature and virtual screening technique 
Triclosan analogues, pyrazole, thiazolidinone, oxazepine, etc., possess promising 
enoyl ACP reductase inhibiting action on both Plasmodium falciparum and 
Escherichia coli.  
Based on these reports an attempt was made here to design and develop 
new antiplasmodial and antibacterial agents by utilizing computational tools. The 
primary objective of the present work is to identify and synthesize pyrazole linked 
thiazolidinone, oxazepine and benzoxazepine as promising antiplasmodial and 
antibacterial agents by the inhibition of enoyl ACP reductase enzyme.  
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PLAN OF WORK  
 The present work has been carried out under the following sections.  
 
Phase I -  In-silico  studies  
 Selection of Target & Lead Molecule by virtual screening 
 Lead Optimization 
 Docking of the Lead molecules  
 
Phase II - Synthesis  
 3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-phenyl-1,3-thiazolidin-4-
 one (2a-j) 
N
N
CH3
N
S
O
R
3
R
2
R
1
 
Pyrazolyl Thiazolidinone series (2a-j) 
 
 3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-phenyl-2,3-dihydro-1,3-
 oxazepine-4,7-dione (3a-j) 
N
N
CH3
N
O
O
O
R
3
R
2R
1
 
Pyrazolyl Oxazepine series (3a-j) 
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 4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-phenyl-3,4-dihydro-2,4-
 benzoxazepine-1,5-dione (4a-j) 
N
NCH3
N
O
O
O
R
2
R
3
R
1
 
Pyrazolyl Benzoxazepine series (4a-j) 
     Spectral characterization 
 
PHASE III - Biological studies  
 Antimalarial Studies (Plasmodium falciparum) 
 Antibacterial Studies (Escherichia coli) 
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CHEMISTRY 
4.1 PYRAZOLES
[75,76]
 
 Pyrazole was first described by Buchner who discovered it during the 
decomposition of pyrazole 3,4,5-tricarboxylic acid. Pyrazole is a colourless solid 
with a melting point of 70°C and is soluble in water. It possesses a penetrating 
pleasant smell. Pyrazole has a high boiling point of about 187°C. 
Synthetic methods 
 The pyrazoles can be synthesized by the following general methods 
1. From (3+2) Cyclization Reaction 
 Pyrazoles are synthesized by the condensation of 1,3-difunctionalized 
compounds with hydrazine or its derivatives involving (3+3) cyclization. 
 Reaction of β-diketones with hydrazine  
 The most widely used method and involves the reaction of β-diketones 
with hydrazine or monosubstituted hydrazine in the presence of an acid. 
CH3
C
H2C
C
CH3
O
O
+ NH2 NH2
CH3
C
H2C
C
CH3
N
O
NH2
N
N
H
CH3
CH3
OH
N
N
H
CH3
CH3
-H2O
 
 Reaction of α,β-ethylenic carbonyl compounds, substituted with a readily 
replaceable substituent of α- or β- position, with hydrazines results in the 
formation of expected pyrazoles. 
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H5C6
C C
CH C6H5O
Cl
C2H5OH
H5C6
C C
CH C6H5N
Cl
H5C6HN+
NH2 NHC 6H5
-HCl
H5C6
C C
CH C6H5N
NH C6H5
CH
C
C
N
N
H5C6
C6H5
C6H5
 
2. 1,3-dipolar cycloadditions 
 1,3-Dipolar cycloaddition of diazoalkanes with functionalized alkynes 
results in the formation of pyrazole. The reaction proceeds through a transition 
state involving energetically most favourable interaction of 4π-electron of 1,3-
dipole [ diazoalkene-with electrophilic and nucleophillic centres-ambivalent] with 
2π-electron of dipolarophile (methylpropiolate)(HOMO of diazoalkene-LUMO of 
dipolarophile). 
N
-
N
CH2
+
N
-
N
+
CH2
NH
N
CH2
-
+
CH
COOCH3
N
N
CH2CH
COOCH3
N
N
CH2
C
CH
COOCH3CHC
N
N
H
COOCH3
CHC
NH
N
COOCH3
 
3. From other ring system 
 Various heterocyclic compounds transform to pyrazole under appropriate 
condition. Syndone, for instance, and acrylonitrile result in pyrazole formation. 
The cyanopyrazole formed as intermediate is immediately converted to pyrazole. 
O
N
C
N
+
O
-
C6H5
+ CH2 CHCN N
N
C6H5
+ CO2 + HCN
70 oC
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Electrophilic Reaction 
 N-Alkylation 
 The alkylation of the free NH group of pyrazole proceeds with alkylating 
agents such as alkyl halides, diazomethane or dimethylsulphate, Substituted 
pyrazoles undergo alkylation to give a mixture of two isomeric products. Excess 
of alkylating agent causes quarterisation. 
N
N
H
R
+ (CH3)2SO4
Base
CH+3
N
N
R
CH3
+
N
R
CH3
a: R=CH3
b: R=C6H5
(65%) (35%)
 
 N-Acylation 
 Pyrazole with free N-H group undergo acylation when treated with 
acetylchloride (alone in the presence of pyridine) or acetic anhydride. 
N
N
H
R
CH3
N
N
H
R
CH3
N
N
R
COR
'
N
N
R
COR
'
(Major product)
(Minor product)
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 Nitration 
 Nitration of pyrazole with nitrating mixture of concentrated nitric and 
sulphuric acids occured at the position-4. 
N
N
H
+ HNO 3
H2SO4
NH
+
N
H
O2N
 
 If the pyrazole is substituted with phenyl group at the position-1, it 
competes with pyrazole ring and nitration occurs at para-position. 
N
N HNO3
H2SO4  ( 10 
oC)
N
N
O2N
HNO3
H2SO4  (20 
oC)
N
N
O2N
O2N
HNO3
H2SO4 (100 
oC)
N
N
O2N
O2N
NO2
 
 Sulphonation 
 Pyrazole undergo sulfonation only under vigorous reaction conditions with 
the introduction of sulfonic acid group at the position-4. 
N
N
H
R
R
H2SO4 + SO3
20% Oleum
Prolonged
heating
N
N
H
R
R
O3SH
 
 Halogenation 
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 Halogenation of pyrazole usually occurs at the position-4. Pyrazoles can 
be chlorinated by chlorinating reagents such as chlorine water, chlorine in carbon 
tetrachloride, chlorine in acetic acid. Pyrazole are brominated by bromine in 
chloroform and bromine in acetic acid. 
N
N
H
N
N
H
Cl
N
N
H
Br
SO2Cl2
Br2
CH3COOH
 
 Reaction with oxidation and reducing agents 
 The pyrazole ring is remarkably stable to the action of oxidizing agents but 
the side chain may be oxidized to the carboxylic function. The oxidation proceeds 
well in the presence of alkaline potassium permanganate. Pyrazole and its 
derivatives have been reduced under a variety of condition. Thus with 
Na/C2H5OH, 2-Pyrazoline in obtained 
N
N
CH3
C6H5
N
N
COOH
C6H5
Alk. KMnO4
Heat
 
 The catalytic reduction of 1-phenylpyrazole yields both phenylpyrazoline 
and 1- phenylpyrazolidine. 
N
N
C6H5
Pd, H2
20 oC
N
N
C6H5
Pd, H2
20 oC
NH
N
C6H5  
Nucleophilic reactions 
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Pyrazole are reactive, but the electron-withdrawing substituent attached at 
α- to the halogen atom makes reactive towards nucleophillic substitutions. 
Pyrazoles exist partly as anions and thus react with electrophiles as phenols and 
undergo diazocoupling, nitrosation and Mannich reaction. 
 Ring cleavage via deprotonation 
 Pyrazole ring unsubstituted at the position-3 is cleaved by a strong base 
(NaNH2) via deprotonation at C-3. 
N
N
H
R
NaNH2
N
N
R
-

C
N
-
N
R
H+
RNH
CN
 
 Photochemical reaction 
 Pyrazole photochemically transformed into imidazoles involving the 
exchange of positions N-2 and C-3 of pyrazole with  the position C-2 and N-3 of 
imidazole. 
N
N
H
R
1
R
2
R
3
h
N
N
H
R
2
R
3
R
1
 
 
 
 
4.2 THIAZOLIDIN-4-ONE
[77] 
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 Compounds containing thiazolidi-4-one nucleus find unique place in 
medicinal chemistry and play significant role as, they are associated with immense 
biological activity. 
 Thiazoles are five membered heterocyclic ring system with sulphur and 
nitrogen in first and third positions respectively. Thiazolidine is nothing but the 
saturated ring system of thiazole. 4-thiazolidinone are derivatives of Thiazolidines 
with the carbonyl group in the 4
th
 position  
             
N
S
N
H
S
N
H
S
N
H
S
O
Thiazoles Thiazoline Thiazolidine 4- Thiazolidinone
 
 Thiazolidi-4-ones are important compounds due to their broad range of 
biological activities. Thiazolidine-4-one have a broad spectrum of 
pharmacological properties i.e., antifungal, antitubercular, antimicrobial, 
antioxidant, antibacterial, anti-inflammatory, analgesic, Anti-YFV activity. The 
most important naturally occurring thiazole derivatives is thiamine (vit B1) which 
contain pyrimidine and thiazole ring system. Penicillins are also important 
naturally occuring products and contain reduced thiazole ring system 
(thiazolidine) 
N
+
S
N
N
HOH 2CH2C
CH3
NH2
CH3
Thiamine (Vitamin B 1)             
N
S
O
HOOC
H3C
H
H
H3C
NHCOR
H
Penicillin G (R = CH 2C6H5)  
SYNTHESIS  
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 2-Substituted thiazolidin-4-ones are easily prepared by the reaction 
between chloroacetic acid, or its derivatives, and a thiourea, a 
thiosemicarbazide, or a mono- or di-thiocarbamate. 
C
CH2
O
Cl
X
+
NH
S YH
R
3
N
S
O
Y
R
3
Chloroacetic acid Di-thiocarbamate 2-sub thiazolidin-4-one
 
 Reaction of α-Haloalkanoic acid with primary amine (Hantzsch 
 synthesis) 
 Substituted 2-imino-4-thiazolidinones are obtained in good yields by the 
reaction of symmetrical and unsymmetrical thioureas with various substituted and 
unsubstituted α-haloalkanoic acids, their esters, acid chlorides, amides, or 
carbamates. The proceeds via the intermediate isothiourea which cyclizes while 
refluxing with acetic acid, ethanol, or benzene in the presence of sodium acetate 
or pyridine. 
C
S
NHR 1NHR C
S
NR1RNH
+ C
R2
X COY
R3
NH
C
C
S
R2
R3
RO Y
NR1
-HYN
S
OH R
NR1
R2
R3
Thiourea
-Haloalkanoic acid
2-imino-4-thiazolidinones
 
R = Alkyl, aryl or heterocyclic, R I = Alkyl, aryl or heterocyclic, 
R2 = H or alkyl, R3= H or alkyl, R2R3= Alkylidene or arylidene. 
 From α-Bromosuccinic acid 
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 α-Bromosuccinic acid mixed with dithiocarbaminates on neutralisation 
with NaHC03 followed by acidification and boiling yields  
2-thiono-4-oxo-5-thiazolidineacetic acids. However, α-bromosuccinic acid on 
treatment with thioureas in the presence of sodium acetate in methanol yields 2-
imino-4-oxo-5-thiazolidineacetic acids. 
C
C
O OH
HOOCH2C H
Br
+
N
KS S
H R
N
S
O
H
HOOCH2C
S
R
-Bromosuccinic acid Dithiocarbamates
2-thiono-4-oxo-5-thiaz-
lidine acetic acids
 
NH2 C
S
NH2
N
NH SH
H H
+
C
C
OOH
CH2COOH
Br
H
N
S
O
H
CH2COOH
NH
H
Thiourea -Bromosuccinic acid 2-imino-4-oxo-5-thiaz-
lidine acetic acid
 
 2-Imino-4-oxo-5-thiazolidineacetic acids can also be synthesized in good 
yields by refluxing equimolar amounts of substituted and unsubstituted thioureas 
and maleic anhydride in acetone. 
N
NHR 1
S
RH
N
NHR 1
SH
RH
+
CH C
HC
O
C
O
O
N
SH
O R
H
HOOCHC
NR1
N
S
O R
H
HOOCH2C
NR1
Maleic anhydride Thiourea
2-Imino-4-oxo-5-thiaz
-olidineacetic acids
 
 3-Carboxyalkyl-2-thiono-4-thiazolidinones have been synthesized from 
long-chain amino acids, NH2-(CH2)nCOOH. The amino acids react with 
CS2 and chloroacetic acid in the presence of bases to give the 
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corresponding N-substituted-4-thiazolidinones through the intermediate 
formation of dithionate. 
NH2(CH2)n COOH + CS2 SK C
S
NH(CH 2)nCOOH
N
S
S
O
(CH2)nCOOH
Cl CH2COOH
K2CO3
 
 Various N-substituted acetylthioacetamides on treatment with 
monochloroacetic acid in the presence of sodium acetate in refluxing 
acetic acid yield 2-acetylmethylene-3-substituted-4-thiazolidinones. 
RNH C
S
CH2COCH3 + ClCH2COOH
N
S
O
CHCOCH3
R
 
 The α-chloro acid derivatives react with metallic thiocyanates yielding an 
intermediates, the cyclization of which gives a 2-iminothiazolidin-4-one. 
C
CH2
O X
Cl
+ MSCN
C
H2C
O X
S
C
N NH
S
O
NH
 
 Various 3-substituted-2-thiono-4-thiazolidinones can be conveniently 
prepared by the reaction of substituted isothiocyanates with                       
α-mercaptoacetic acid or its ester followed by acid cyclization of the 
resulting (thiocarbamoyl) mercaptoacetic acids and acetates. 
RNCS + SHCH2COOR1
S
RNH SCH2COOR1
N
S
O
S
R
 
 Schiff bases obtained by the condensation of ketones and amines also react 
with α-mercaptoacetic acid to give 2,2-disubstituted-4-thiazolidinones. 
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NR C
R
1
R
2
+ SHCH2COOH C
R
1
SCH2COOH
RNH R
2
N
S
O R
R
2
R
1
 
 β-aryl-α-mercaptoacryllic acids add to the C=N bond of schiff’s base 
affording thiazolidin-4-ones. The addition to the same acid to phenyl 
isothiocyanate yields 5-arylidene-3-phenylrhodanines. 
C
C
O
OH
C
SH
H
Ar
+
C
N
R
3
H Ph
N
S
O R
3
HCAr Ph
C
N
Ph
S
N
S
O R
3
HCAr S
-aryl--mercaptoac
-ryllic acids
Schiff's base
Phenyl 
isothiocyanate
 
 An interesting synthesis of substituted thiazolidin-4-one 1,1- dioxides 
results from 1,3-dipolar addition of the adduct of ketene and sulphur 
dioxide(18a) with benzylidene aniline. The ketene-sulfur dioxide adduct 
may be represented by a mesomeric structure which corresponds to a 
linear 1,3-dipolar species(18b). 
SO2H2C
O
H2C
C
+
SO2
O
+
N
H Ph
Ph
SO2
N
HO
Ph
 
CHEMICAL REACTION 
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 Thiazolidin-4-one presents three nucleophilic centres (C-5, oxygen and 
nitrogen) and two electrophilic centers (C-4 and C-2)  
 Electrophilic attack at Carbon 
 The reactivity of thiazole ring is further lowered in electrophilic 
substitutions proceeding under acidic conditions (nitration, sulfonation and 
Friedel-Crafts reaction) because of the protonated thiazole. However, thiazoles 
undergoes electrophilic substitutions readily if the thiazole ring is substituted with 
electron-releasing substituents (-OH and –NH2). The attack of electrophiles occurs 
preferentially at the position-5 of the thiazole ring 
 Sulfonation 
 Thiazole sulfonation occurs only under forcing conditions by the reaction 
with oleum at 250°C for 3 hours in the presence of Mercury(II)sulphate leads to 
65% formation of 4-thiazole sulfonic acid. However, 2-aminothiazole is 
sulfonated at low temperature 0°C affording at first the formation of 2-sulfamic 
acid which on heating rearranges to 2-aminothiazole-5-sulfonic acid 
S
N
NH2 S
N
NHSO 3H S
N
NH2HO3S
H2SO4
0 oC

 
 Nitration 
 No nitration of thiazole occurs with the classical nitration reagents, even 
under forcing conditions. 
 
 
 Halogenation 
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 Unsubstituted thiazole does not react with Cl or Br in an inert solvent, but 
2-methylthiazole undergoes bromination at the position-5 (if the position-5 is 
occupied, the bromination does not occur. However, the presence of electron 
releasing substituent at the position-2 facilitates bromination at position-5 even 
under the mild condition. 
S
N
CH3 S
N
NH2Br
S
N
CH3CH3
No reaction
S
N
NH2 S
N
NH2Br
Br2
CHCl3
Br2
Br2
CH3COOH
 
 Alkylation 
 Thaizoles activated by the substituents substituted at the position-2 and -4 
undergo alkylation at the position -5 when treated with tert-butyl alcohol in the 
presence of sulphuric acid. 
S
N
NH2
CH3
+ (H3C)3C OH
S
N
NH2
CH3
(H3C)3C
H2SO4
 
 
 
 
 Oxidation 
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 Thiazole is relatively resistant to oxidation. Under photosensitized 
oxygenation, triphenylthiazole affords various products of ring cleavage, 
depending on the sensitizer and solvent. 
S
N
Ph
Ph
Ph
+ O2
Ph
C C
Ph
CH2 CH2
+
Ph
C
NH2
O
Ph
C
N
S
COPh
COPh
MeOH
CHCl3
Methylene 
blue
Rose Bengal
 
 Diazo coupling 
 Only 2-aminothiazole derivatives are reductive enough toward diazonium 
salts undergo the diazo coupling reaction. The azo group substitutes exclusively at 
the position-5 when the later is unsubstituted. 
S
N
NH2
CH3
+ N
+
N
NO2
O2N
S
N
NH2
CH3
NN
NO2
O2N
 
  Desulfurization  
Thiazoles undergo desulfurization when treated with Raney nickel, but the 
products formation depends upon the reaction condition. 
S
N
R
1
R
2
C N
R
2
CH3 CH2R
1
Hydrolysis
H2O
C O
R
2
CH3
+
C N
R
2
CH2SH
R
1 OH
C N
R
2
CH3 CH2R
1
OH
C NH2
R
2
CH3
+ R
1
CHO
Ni/H2
Ni/H2
Ni/H2
Neutral 
conditions
Alkaline 
condition
R
1
CH2NH2
 
Reactions with nucleophiles 
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 Nucleophilic attack at carbon 
 In the thiazole ring, the position-2 is with lowest π-electron density 
(position-4 almost neutral and position-5 slightly electron-rich) and is, therefore, 
most susceptible for the nucleophillic attack (requires activation or strong 
ncleophiles). 
 Amination 
 Thiazoles can be aminated at the position-2 by treating with sodium amide 
at 150°C with the transfer of hydride ion. 
S
N
CH3
+ NaNH 2
S
N
NH2
CH3

150 oC
 
 Ring cleavage 
 Thiazole are resistant to attack by hydroxide ion, but thiazolium cation 
(salts) are susceptible towards attack of hydroxide ion under mild conditions and 
results in the cleavage of the ring. 
S
N
+
H
R
S
NH
O
R
2
H H
SH
N
CH
O
R
S
-
N
CH
O
R
 
 
 
 Metal –Halogen Exchange 
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 2-Halothiazoles undergo halogen metal exchange when treated with n-
butyllithium and Grignard reagents. 
S
N
Br
n - BuLi
C2H5MgBr
S
N
Li
S
N
MgBr
 
 Metallation 
 Thiazoles are deprotonated preferentially at C-2 by a strong base. Thus 
thiazole is metallated with the abstraction of acidic hydrogen at C-2 when treated 
with n-butyllithium or ethyl magnesium bromide. 
S
N
+ C2H5MgBr
S
N
MgBr
ether
0 oC - 25 oC
 
 Reaction at oxygen atom 
 The nucleophilic reactivity of the oxygen atom has been observed in the 
acetylation by acetic anhydride of 2-aryl- and 2-heteryl-thiazolin-4-one. 
S
N
R
O
S
N
R
AcO
Ac2O
Pyridine
 
 
4.3  OXAZEPINE
[78-80]
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 Oxazepine chemistry includes some interesting rearrangement rections 
both in synthesis and reactivity, many of which have parallels in the chemistry of 
the analogous diazepine system. 
 
O
N
O
N
O
N
1,2-Oxazepine 1,3-Oxazepine 1,4-Oxazepine
 
  1,3-Oxazepine is unsaturated seven-membered heterocycle consist of 
oxygen atom in location (1), nitrogen atom in location (3) besides of five carbons. 
They have been studied the molecular properties of this pharmaceutically 
important nucleus belong to its entity in some natural products and compounds 
biological active as antithrombotic, antiepileptic, anticonvulsant, anti-
inflammatory, antifungal, progesterone agonist, antipsychotic, antagonist and 
analgesic, antihistaminic, anxiolytics, epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitory and antiaggregating activities 
 
Synthesis 
 Type a (C-N-C-C-C-C-O) 
 Formation of this type of bond usually involves ring closure via 
nucleophilic attack by oxygen on an electrophilic carbon, e.g., a carbonyl group or 
carbon-halogen bond. Thus 2-methyl-4,5,6,7-tetrahydro-1,3-oxzepine can be 
prepared by the distillation of 4-acetyl-aminobutanol. The copper-catalysed 
insertion of isocyanide into the O-H bond of alcohols gives a high yielding route 
to 4,5 -dihydro-3,1-benzoxazepines. 
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R
1
R
2
CHLi
R
3
NC + O
R
4
R
5
R
1
R
2
CHC
R
3
R
4
R
5
OH
NC
O
N
R
3
R
4
R
5
R
1
R
2
Cu2O
Synthesis from other heterocyclic systems 
 The photochemical rearrangement of aromatic N-oxides, provides one of 
the major route to the fully unsaturated 1,3-Oxazepine system. The 
reaction is thought to proceed by the primary formation of an oxaziridine 
intermediate which rearranges by a 1,5-sigmatropic shift to give which is 
then converted to the product by a disrotatory ring opening. 
N
+
O
-
C
N
+
O
Ph
N
O
Ph
Ph
Ph Ph
Ph
Ph
Ph
Ph
O
N
Ph
Ph
Ph
 
 Monocyclic 1,3-oxazepine with aryl substituents at the 2-, 4- and 7-
positions can be prepared in moderate yield (20%-40%) by the reaction of 
aliphatic diazo compounds with 1,3-oxazinium perchlorates. 
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 The preparation of 2-phenyl-1,3-oxazepine by the UV irradiation of is 
mechanistically  interesting in that it apparently involves an intermediates. 
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 1,3-oxazepine ring synthesis of utilized a pericyclic reaction, was 
classified as (2+5) cycloaddition reaction in which two atoms of the first 
component (azomethine ) react with five-membered component such as 
phathalic or maleic anhydride to give seven-membered heterocycle. 
Mechanism of the pericyclic reaction for the synthesis 1,3-oxazepine ring 
is shown below 
 
 Reactivity 
 1,3-Oxazepine are not very stable compounds and are easily decomposed 
by heat, light, acids and bases to a variety of products. In some of their 
reaction paths it seems likely that decomposition takes place via hydrolytic 
opening of the oxazepine but in others via conversion to the 
oxazanorcaradiene valence tautomer, e.g. 
N
COPh
O
N
Ph
N
O
Ph N
OH
Ph
HCl
20 
o
C
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 Photochemical reaction 
 The photolysis of in aprotic solvents gives the labile 3H-indole 
intermediate as the primary photoproduct but in methanol, the addition 
reaction which gives is faster. 
O
N
R
R
1
N
CHO
R
1
R
h
Aprotic
h/MeOH
R1= CO2Me
R= Ph
OMe
CO2Me
NHCOPh
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4.4  SYNTHESIS OF 2,4-BENZOXAZEPINE 
 From 2-(Amino-methyl)benzyl acohol 
 2-(Amino-methyl)benzyl acohol cyclises with phosgene in alkali to 
 give 1,,3,4,5-thetrahydro-2,4-benzoxazepin-3-one. 
CH2NHR
CH2OH
R
1
Phosgene
alkali
O
N
H
O
 
Reactivity 
 The reactivity and stability in acidic or basic media of 2,4-benzoxazepin-3-
one was found to be the heterocyclic nucleus readily opens in warm dilute 
alkali to give o-Aminomethyl benzyl alcohol and N,N’-bis-o-hydroxy-
methylbenzyl urea. 
O
N
H
O
Alkali, H2O
-OH
CH2NH2
CH2OH
+
CH2NH
-
CH2OH
2
CO
 
 The acylation of 2,4-benzoxazepin-3-one the compound decomposes on 
reaction with both aliphatic and aromatic acid chlorides. So, the 
corresponding N-acyl derivatives  (N-Acetyl-4,5-dihydro-2,4-
benzoxazepine-3(1H)one) were isolated by heating 2,4-benzoxazepin-3-
one with an aliphatic anhydride; with an aromatic anhydride such as 
benzoic anhydride the ring-opened compounds o-Benzamidomethylbenzyl 
Benzoate was obtained. 
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O
N
H
O
Acetic anhydride
O
N O
COCH3
(C6H5CO)2O
CH2NHCOC6H5
CH2OCOC6H5  
 Benzoxazepine reacted normally with phenyl isocyanate to yield the N-
phenylcarbamoyl derivative. Reaction with ethylene oxide in methanol 
gives methyl o-hydroxymethylbenzylcarbamate. 
O
N
H
O
C6H5NCO
O
N
COOC6H5
O
 
 Methylation of Benzoxazepine with methyl iodide to give the 
 methylated product. 
O
N
H
O
CH3I
O
N O
CH3
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MATERIALS AND METHODS 
5.1.  PHASE 1: INSILICO STUDIES 
 Software and databases used 
 iGEMDOCK v.2 
 Zinc database 
 Cygwin 
 Mgltools 1.5.6 
 Autodock tools 1.5.6 
 Python 3.4.3 
 Discovery studio visualizer 
 Molinspiration server 
 RCSB Protein data bank 
 Online simile translator 
 All the in-silico experiments are carried out in Department of 
Pharmaceutical Chemistry, College of Pharmacy, Sri Ramakrishna Institute of 
Paramedical Sciences, Coimbatore. 
5.1.1 Virtual Screening  
 Identification of drug target 
 Selection of the lead 
Procedure: 
 Virtual screening is done by using iGEMDOCKv.2.
 [81-83] 
 
1. Using ZINC, the free data base of around thirteen million commercially 
available compounds, a small molecule library consisting of 48 
compounds were constructed. The protein with the accession code 1VRW 
& 1C14 corresponding to enoyl ACP reductase of P. falciparum and E.coli 
was selected from the RCSB protein data bank. 
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2. The protein was uploaded in the iGEMDOCKv.2 & the binding sites 
 were chosen. 
3. Similarly ligands were uploaded in the iGEMDOCKv.2 
4. Start virtual screening module was clicked & the fitness value was  saved. 
RESULTS AND DISCUSSION 
 Among the 48 PfENR & E.coli FabI inhibitors screened, pyrazole, 
thiazolidinone, oxazepine were identified as the lead. The results are tabulated in 
Table1 and the snap shots of ligands binding with 1VRW.pdb and 1C14.pdb are 
given in fig.9, 10. 
    
Fig.9: Binding of ligands with 1VRW.pdb 
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Fig.10: Binding of ligands with 1C14.pdb 
Table.1: Fitness values of 48 compounds 
S.No Compound code 
Fitness value 
1VRW 1C14 
1 ZINC-6316009 -106.7 -90.36 
2 ZINC-633953 -88.85 -107.17 
3 ZINC-664768 -119.81 -107.28 
4 ZINC-666178 -104.39 -106.31 
5 ZINC-667115 -96 -103.47 
6 ZINC-856315 -112.56 -118.35 
7 ZINC-857211 -99.68 -98.28 
8 ZINC-878056 -116.23 -110.95 
9 ZINC-1240782 -91.06 -104.91 
10 ZINC-2063825 -84.76 -106.61 
11 ZINC-2064406 -112.11 -104.84 
12 ZINC-2124704 -106.37 -99.53 
13 ZINC-2258599 -81.35 -75.67 
14 ZINC-3770286 -115.98 -103.04 
15 ZINC-4180918 -123.71 -94.4 
16 ZINC-8441250 -85.94 -103.42 
17 ZINC-8441387 -99.23 -108.69 
18 ZINC-8441604 -121.98 -102.08 
19 ZINC-8441700 -97.79 -99.24 
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S.No Compound code 
Fitness value 
1VRW 1C14 
20 ZINC-8441816 -105.18 -116.45 
21 ZINC-8441888 -101.68 -112.39 
22 ZINC-8441912 -103.26 -88.53 
23 ZINC-8441938 -95.72 -87.42 
24 ZINC-844194 -101.85 -102.28 
25 ZINC-8441955 -96.54 -103.2 
26 ZINC-8441959 -91.78 -101.43 
27 ZINC-8441975 -91.72 -107.13 
28 ZINC-8441999 -105.68 -97.98 
29 ZINC-8442087 -112.52 -116.35 
30 ZINC-8442127 -109.34 -103.02 
31 ZINC-8442156 -84.77 -111.38 
32 ZINC-8442161 -103.86 -110.47 
33 ZINC-8442164 -98.51 -109.49 
34 ZINC-8442165 -94.44 -94.75 
35 ZINC-8442166 -91.38 -103.21 
36 ZINC-8442180 -103.51 -129.53 
37 ZINC-8442267 -99.99 -124.28 
38 ZINC-8442295 -101.52 -113.19 
39 ZINC-19794473 -97.82 -104.73 
41 ZINC-19794496 -100.18 -95.71 
42 ZINC-19795380 -82.84 -98.43 
43 ZINC-19795548 -95.87 -93.67 
44 ZINC-3770286 -108.44 -98.01 
45 ZINC-3788342 -102.95 -91.21 
46 ZINC-2258574 -100.63 -93.12 
47 ZINC-2258650 -107.13 -111.45 
48 ZINC-2254930 -113.29 -111.82 
49 ZINC-2255236 -94.82 -101.07 
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By analysing the results, the compounds containing PYRAZOLE, 
THIAZOLIDINONE and OXAZEPINE nucleus were found to have good 
fitness value. Therefore on the basis of the virtual screening performed in 
iGEMDOCK v2.1 and by the literature, pyrazole linked with thiazolidinone and 
oxazepine were taken as the lead for PfENR and E.coli FabI inhibitors in the 
present study. 
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5.1.2 LEAD OPTIMIZATION 
 Lead optimization was done by evaluating the drug likeness properties 
Computation of drug like properties 
 Lipinski’s rule of five help to find the drug likeness score. For the better 
oral absorption of the ligands, the drug likeness scores are constructed by getting 
information about the solubility, diffusion, Log P, molecular weight etc. 
Lipinski’s rule of five can be found out by utilizing Molinspiration server. 
Calculation of Lipinski’s rule of five [84] 
1. Open the Molinspiration home page.  
2. Click calculation of molecular properties and prediction of  bioactivity.  
3. Draw the structure of 2a in JME window or paste the smile notation 
 of      the compound. 
4. Then click calculate properties.  
5. save the properties.  
6. JAVA program is required in the computer for the calculation of the 
 properties.  
 Calculation of properties of the rest of the compounds is done in the same 
manner. Results are tabulated in Table 2. 
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RESULTS AND DISCUSSION 
Table.2: Drug likeliness scores of 2a-j and 3a-j ligands 
S.No Compound 
code 
Log P Molecular 
Weight 
Hydrogen 
acceptors 
Hydrogen 
donor 
n 
Violations 
1 2a 3.32 380.43 7 0 0 
2 2b 4.06 369.88 4 0 0 
3 2c 3.44 365.46 5 0 0 
4 2d 2.73 381.46 6 1 0 
5 2e 3.49 378.50 5 0 0 
6 2f 4.01 369.88 4 0 0 
7 2g 3.10 395.48 6 1 0 
8 2h 2.60 353.40 6 2 0 
9 2i 2.81 381.46 6 0 0 
10 2j 3.33 339.39 4 0 0 
11 3a 2.96 390.36 9 0 0 
12 3b 3.70 379.80 6 0 0 
13 3c 3.08 375.38 7 0 0 
14 3d 2.36 391.38 8 1 0 
15 3e 3.12 388.43 7 0 0 
16 3f 3.65 379.80 6 0 0 
17 3g 2.73 405.41 8 1 0 
18 3h 2.46 377.36 8 2 0 
19 3i 2.67 405.41 8 0 0 
20 3j 3.18 363.35 6 0 0 
21 4a 4.29 454.47 9 0 0 
22 4b 4.81 429.86 6 0 0 
23 4c 4.19 425.44 7 0 0 
24 4d 3.47 441.44 8 1 0 
25 4e 4.24 438.49 7 0 0 
26 4f 4.76 429.86 6 0 0 
27 4g 3.85 455.47 8 1 0 
28 4h 3.57 427.42 8 2 0 
29 4i 3.78 455.47 8 0 0 
30 4j 4.52 427.44 6 0 0 
 The in-vivo absorption capabilities of the designed molecules were 
assessed by means of Lipinski’s rule of five using molinspiration server. All the 
lead compounds satisfied the rule indicating that ligand 2a-j, 3a-j and 4a-j have 
good oral absorption. 
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5.1.3  DOCKING STUDIES FOR THE LEAD MOLECULES
 [85-89]
 
 From the virtual screening and literature review we have selected Enoyl 
Acyl Carrier Protein Reductase PfENR & FabI as a target for the present 
study. The enzyme have been selected from RCSB Protein Data Bank where the 
x-ray crystallographic structures were obtained and the docking studies were 
performed with the AutoDock 4.2 version.  
 Various steps involved in docking are 
Step 1: SELECTION FROM PDB 
  Plasmodium falciparum : PDB accession code:1VRW.pdb (PfENR) 
  Escherichia coli : PDB accession code: 1C14.pdb (E.coli FabI) 
 Target proteins were downloaded from RCSB Protein Data Bank and 
docking studies were performed. 
Step 2: PROTEIN STRUCTURE REFINEMENT  
 Protein (1VRW & 1C14) downloaded from protein data bank as such 
cannot be used for docking process. It has to be refined before docking. 
Refinement of downloaded protein involves the removal of water and bound 
ligand if any. 
The steps involved are 
 Open Discovery studio viewer. 
 File         open        Protein (downloaded from PDB). 
 View          Hierarchy. 
 Click water molecule. 
 Ctrl + shift and click the last water molecule (select all the water 
 molecule) 
 Give right click and cut. 
 Select ligand, which is unnecessary. Give right click and cut. 
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 Save the molecule in our desired area. 
 The 1VRW.pdb and 1C14.pdb were refined by the above method. 
Step 3: LIGAND FILE FORMAT CONVERSION 
 The ligands 2a-j, 3a-j and 4a-j were drawn in Chemsketch. 
 Tools      Generate        SMILES notation [Simplified Molecular Input 
 Line Entry System, which is a file format] 
 Save the SMILES in a word document. 
 Open the online smile translator – catus. nci.nih.gov/services/translate/ 
 Upload the SMILES 
 By choosing the required file format we can save the file. Here, we are 
 saving it as pdb format in Cygwin/usr/local/bin. 
 
 Online smile translator allows the user to convert SMILES format into 
PDB, MOL, SDF and smile text file format. Thus the selected ligand molecule of 
canonical smile formats was converted to pdb formats. The protein and ligand 
files which are prepared by above said procedures were taken for docking. 
Step 4: DOCKING 
 Docking was performed using AutoDock and requires a refined protein 
and the ligand in PDB format and files like autogrid4 and autodock4. 
 Docking process is done with AutoDock 4.2 
Steps involved are 
 Conversion of refined enzyme into .pdb format. 
 Conversion of pdb format of ligand into .pdbqt format.  
 Preparation of grid box by setting grid parameters at 60, 60 & 60. 
 Docking process by setting docking parameters. 
 Saving the docked result as .dlg file. 
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 Viewing the docked conformation. 
 Taking snapshots of the interactions. 
 Docking studies for all the ligands 2a-j, 3a-j and 4a-j were carried out in 
the same manner. 
RESULTS AND DISCUSSION 
 The docking results of Pf-ENR (1VRW.pdb) & E.coli FabI (1C14.pdb) 
with the ligands 2a-j, 3a-j and 4a-j and standard are reported below. The best 
docked structures should have the binding energy lower to the standard. The 
binding sites and the active sites are represented in the snap shots and the binding 
energy was compared with the standard ligand, triclosan.  
 The results have been tabulated in the Table 3 followed by the snapshots. 
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Table 3: Binding energies of 2a-j with Pf-ENR (1VRW.pdb) & 
 E.coli-FabI 1C14.pdb) 
S.No Compound code 
Binding energies (kcal/mol) 
1VRW.pdb 1C14.pdb 
1 2a -5.68 -4.54 
2 2b -4.78 -5.71 
3 2c -6.59 -3.54 
4 2d -6.43 -4.41 
5 2e -2.89 -3.88 
6 2f -2.93 -1.66 
7 2g -7.26 -4.66 
8 2h -3.89 -5.69 
9 2i -4.36 -2.85 
10 2j -6.10 -4.01 
11 3a -9.33 -1.24 
12 3b -9.51 -4.91 
13 3c -5.39 -7.58 
14 3d -5.88 -6.65 
15 3e -7.83 -3.41 
16 3f -9.11 -5.24 
17 3g -6.63 -3.67 
18 3h -9.45 -3.68 
19 3i -7.89   -6.49 
20 3j -6.78 -3.27 
21 4a -7.31 -8.05 
22 4b -6.43 -7.55 
23 4c -8.76 -8.28 
24 4d -8. 43 -8.24 
25 4e -4.57 -9.09 
26 4f -6.32 -6.91 
27 4g -7.58 -5.65 
28 4h -5.43 -6.57 
29 4i -6.23 -9.19 
30 4j -9.19 -6.23 
31 Triclosan -5.28 -7.15 
Binding interactions of 2g with Pf-ENR (1VRW.pdb) 
Experimental Section 
 
 
 
 
 
Department of Pharmaceutical Chemistry 84 
 2g interacts with Enoyl ACP reductase at Tyr 267, Tyr 277, Met 281, 
Gly313, Pro314 and NAD
+
. The binding energy was found to be -7.26 kcal/mol. 
     
Snap shot of 2g with PfENR (1VRW.pdb) 
 
 
 
 
 
 
 
 
Snapshots of other pyrazolyl thiazolidinone derivatives with Pf-ENR 
(1VRW.pdb) 
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Binding interactions of 3b with Pf-ENR (1VRW.pdb) 
 3b interacts with Enoyl ACP reductase at Tyr 267, Tyr 277, Met 281, 
Gly313, Pro314 and NAD
+
. The binding energy was found to -9.51 kcal/mol. 
 
 
 
 
 
 
 
 
 
Snap shot of 3b with PfENR (1VRW.pdb) 
Snapshots of other pyrazolyl oxazepine derivatives with  
Pf-ENR (1VRW.pdb) 
 
 
 
 
 
 
 
3a 
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3e      3f 
     
3g     3h 
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3i      3j 
Binding interactions of 4c with Pf-ENR (1VRW.pdb) 
 4c interacts with Enoyl ACP reductase at Tyr 267, Tyr 277, Met 281, 
Gly313, Pro314 and NAD
+
. The binding energy was found to be -8.76kcal/mol. 
 
Snap shot of 4c with Pf-ENR (1VRW.pdb) 
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Snapshots of other pyrazolyl benzoxazepine derivatives with Pf-ENR 
(1VRW.pdb) 
      
   4a      4b 
      
      4d      4e 
      
   4f           4g 
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   4h     4i  
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Binding interactions of Triclosan with Pf-ENR (1VRW.pdb) 
 Triclosan interacts with Enoyl ACP reductase at Tyr 267, Tyr 277, Met 
281, Gly313, Pro314 and NAD
+
. The binding energy was found to be -5.28 
kcal/mol. 
 
Snapshot of triclosan with PfENR (1VRW.pdb) 
In the pyrazolyl thiazolidinone series, all the ligands (2a-j) showed 
excellent binding interactions with the PfENR (1VRW.pdb). Among the 
derivatives, 2g (ethoxy), 2c (methoxy), 2d (4-hydroxy-3-methoxy) and 2j (fluoro) 
had shown the highest binding energies, -7.26, -6.59, -6.43 and -6.10kcal/mol . 
Among the pyrazolyl oxazepine (3a-j) derivatives, 3b (p-chloro), 3h (dihydroxy), 
3a (nitro) and 3f (o-chloro) had shown the highest binding energies, -9.51, -9.45, -
9.33 and -9.11kcal/mol. Among the pyrazolyl benzoxazepine  (4a-j) derivatives, 
4j (fluoro), 4c (methoxy), 4d (4-hydroxy-3-methoxy)  and 4g (ethoxy) had shown 
the highest binding energies, -9.19, -8.76, -8.43 and -7.58kcal/mol when 
compared to the standard, triclosan (-5.28kcal/mol). 
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Binding interaction of 2b with E.coli-FabI (1C14.pdb) 
 2b interacts with Enoyl ACP reductase at Gly 93, Leu195, Tyr 158, Ala 
196, Lle 200 and alse with NAD. The binding energy was found to be -5.71 
Kcal/mol. 
 
Snapshot of 2b binding with E.coli-FabI (1C14.pdb) 
Snapshots of other pyrazolyl thiazolidinone derivatives with E.coli-FabI 
(1C14.pdb) 
      
2a     2c 
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2d      2e 
      
2f      2g 
      
2h      2i 
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2j 
Binding interaction of 3c with E.coli-FabI (1C14.pdb) 
 3c interacts with Enoyl ACP reductase at Gly 93, Leu195, Tyr 158, Ala 
196, Lle 200 and alse with NAD. The binding energy was found to be -
7.58kcal/mol. 
 
Snapshot of 3c binding with E.coli-FabI (1C14.pdb) 
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Snapshots of other pyrazolyl oxazepine derivatives with E.coli-FabI 
(1C14.pdb) 
      
3a     3b 
      
3d     3e 
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3h      3i 
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Binding interaction of 4i with E.coli-FabI (1C14.pdb) 
 4i interacts with Enoyl ACP reductase at Gly 93, Leu195, Tyr 158, Ala 
196, Lle 200 and alse with NAD
+
. The binding energy was found to be -
9.19kcal/mol. 
 
Snapshot of 4i binding with E.coli-FabI (1C14.pdb) 
Snapshots of other pyrazolyl benzooxazepine derivatives with E.coli-FabI 
(1C14.pdb) 
      
4a       4b 
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Binding interaction of triclosan with E.coli-FabI (1C14.pdb) 
 Triclosan interacts with Enoyl ACP reductase at Gly 93, Leu195, Tyr 158, 
Ala 196, Lle 200 and also with NAD. The binding energy was found to be -
7.15kcal/mol 
 
Snapshot of triclosan binding with E.coli FabI (1C14.pdb) 
In the pyrazolyl thiazolidinone series, all the ligands (2a-j) showed 
excellent binding interactions with the E.coli FabI (1C14.pdb). Among the 
derivatives, 2b (chloro), 2h (dihydroxy) and 2g (ethoxy) had shown the maximum 
binding energies, -5.71, -5.69 and -4.66kcal/mol. Among the pyrazolyl oxazepine 
(3a-j) derivatives, 3c (methoxy), 3d (4-hydroxy-3-methoxy), 3i (dimethoxy) and 
3f (o-chloro) had shown the maximum binding energies, -7.58, -6.65, -6.49 and                
-5.24kcal/mol. Among the pyrazolyl benzoxazepine (4a-j) derivatives, 4i 
(dimethoxy), 4e (p-dimethyl amino), 4c (methoxy)  and 4a (nitro) had shown the 
maximum binding energies, -9.19, -9.09, -8.28 and -8.05kcal/mol when compared 
to the standard, triclosan (-7.15kcal/mol).  
 
5.2  PHASE II – SYNTHESIS 
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Chemicals and reagents used 
 3-nitro benzaldehyde, 4-chloro benzaldehyde, 4-methoxy benzaldehyde, 4-
hydroxy 3-methoxy benzaldehyde, 4-dimethylamino benzaldehyde, 2-chloro 
benzaldehyde, 3-ethoxy 4-hydroxy benzaldehyde, 2,4-dihydroxy benzaldehyde, 
3,4-dimethoxy benzaldehyde, 4-fluoro benzaldehyde, β-aminocrotononitrile, 
phenylhydrazine, 1N HCl, thioglycolic acid, maleic anhydride, phthalic 
anhydride, dry benzene, dioxan, ethanol, etc.  
 All the chemicals and reagents were procured from Sigma Aldrich, High 
Media and LobaChem. All the compounds procured were purified and dried, 
whenever necessary before use, by following standard methods. 
Analytical work 
 Melting point were determined by using melting point apparatus MR-VIS, 
visual melting range apparatus, LABINDIA and corrected. 
 Reactions were monitored by thin layer chromatography (TLC) on  pre-
 coated silica gel-G plates using iodine vapour as visualizing  agent.  
 UV spectra were recorded on JASCO V-530 UV/VIS Spectrophotometer 
in the Department of Pharmaceutical Analysis, SRIPMS, College of 
Pharmacy, Coimbatore. 
 IR spectra on JASCO FTIR-420 in the Department of 
 Pharmaceutical      Analysis, SRIPMS, College of Pharmacy, Coimbatore. 
 NMR were recorded on the Bruker Ultra Shielded NMR-300MHz. 
 MASS spectra were recorded on JEOL GC Mate GC-MS Spectroscopy. 
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Compd code R1 R2 R3 
a H NO2 H 
b H H Cl 
c H H OCH3 
d H OCH3 OH 
e H H N(CH3)2 
f H Cl H 
g H OC2H5 OH 
h OH H OH 
i H OCH3 OCH3 
j H H F 
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Procedure 
Step 1: Synthesis of 3-methyl-1-phenyl-1H-pyrazol-5-amine
[90]
 
 An amount of 3.48g (0.042 mol) β-aminocrotononitrile was dissolved in 
40ml 0f 1NHCl. To this mixture 5.86g (0.04mol) of phenylhydrazine 
hydrochloride was dissolved and then refluxed for 4 hours. The resulting reddish 
liquid was cooled to room temperature and basified to alkaline p
H
 with aqueous 
sodium hydroxide. The product obtained was filtered and dried. 
Step 2: Synthesis of Schiff base (1a-j)
 [91]
 
 A mixture of 3-methyl-1-phenyl-1H-pyrazol-5-amine (0.005mol) and 
benzaldehyde (0.005mol) were dissolved in minimum quantity of ethanol and few 
drops of glacial acetic acid was added and the mixture was refluxed for 3 hours. 
After cooling, the mixture was added to crushed ice by stirring. The separated 
compounds was filtered, washed, dried and recrystallised from ethanol. 
Step 3:  
 Synthesis of Thiazolidinone derivatives (2a-j)  
 Schiff’s base (0.001 mol) treated with mercaptoacetic acid (Thioglycolic 
acid) (0.002 mol) in dioxin 25ml in presence of anhydrous ZnCl2 and reaction 
mixture was refluxed for 4hrs. After cooling the reaction mixture was poured in 
crushed ice with stirring. Thus the separated solid was then filtered, washed with 
sodium bicarbonate to remove unreacted thioglycollic acid and recrystallized from 
methanol. 
 Synthesis of Oxazepine derivatives (3a-j) 
 To a solution of maleic anhydride (0.01mol, 0.8g ) in 10ml of dry benzene 
was added dropwise to a hot dry benzene solution (20ml) containing 0.01mol of a 
Schiff’s base and the reaction mixture was refluxed for 3hrs. The solvent distilled 
off and the solid obtained was washed with cold water. And the resulting was 
recrystallized from Ethanol. 
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 Synthesis of Benzoxazepine derivatives (4a-j) 
 To a solution of phthalic anhydride (0.01mol, 0.8g ) in 10ml of dry 
benzene was added dropwise to a hot dry benzene solution (20ml) containing 
0.01mol of a Schiff’s base and the reaction mixture was refluxed for 3hrs. The 
solvent distilled off and the solid obtained was washed with cold water. And the 
resulting was recrystallized from Ethanol. 
RESULTS AND DISCUSSION 
 The novel 30 docked compounds(2a-j, 3a-j, 4a-j) were synthesized by the 
schemes as mentioned above and the structure of the synthesized compounds were 
established on the basis of the physical data (melting point and TLC) and spectral 
data (IR, UV, NMR and MASS) respectively. The purity of the compounds was 
established by TLC plates. 
Recrystallisation solvent  : Ethanol 
Solvent system                 : Ethyl acetate: n-Hexane (3:7) 
Visualizing agent       : Iodine vapour 
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PHYSICAL CHARACTERISATION DATA 
1) Pyrazolyl Thiazlidinone series (2a-j) 
N
N
N
S
O
CH3
R
 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-phenyl-1,3-thiazolidin-4-one 
Table 4: Physical characterization of Pyrazolyl Thiazolidinone series (2a-j) 
SI no. Compd code R
1 
R
2 
R
3 
Molecular formula Mol.weight % Yield Melting point °C Rf  value 
1 2a H NO2 H C19H16N4O3S 380.42 67 93.50 0.36 
2 2b H H Cl C19H16ClN3OS 369.86 56 105.34 0.50 
3 2c H H OCH3 C20H19N3O2S 365.44 76 89.61 0.46 
4 2d H OCH3 OH C20H19N3O3S 381.448 54 93.67 0.83 
5 2e H H N(CH3)2 C21H22N4OS 378.49 58 135.32 0.54 
6 2f H Cl H C19H16ClN3OS 369.86 69 120.43 0.43 
7 2g H OC2H5 OH C21H21N3O3S 395.47 45 105.28 0.63 
8 2h OH H OH C18H15N3O3S 353.395 55 118.10 0.48 
9 2i H OCH3 OCH3 C20H19N3O3S 381.44 67 85.34 0.73 
10 2j H H F C18H14FN3OS 339.38 45 98.32 0.66 
2) Pyrazolyl Oxazepine series (3a-j) 
Experimental Section 
 
 
 
 
 
Department of Pharmaceutical Chemistry 106 
N
N
CH3
N
O
O
O
R
3
R
2R
1
 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-phenyl-2,3-dihydro-1,3-oxazepine-4,7-dione 
Table 5: Physical characterization of Pyrazolyl Oxazepine  series (3a-j) 
SI 
no. 
Compd 
code 
R
1 
R
2 
R
3 
Molecular formula Mol. 
weight 
% Yield Melting 
point °C 
Rf  value 
1 3a H NO2 H C20H14N4O5 390.34 56 120.21 0.47 
2 3b H H Cl C20H14ClN3O3 379.79 45 93.84 0.42 
3 3c H H OCH3 C21H17N3O4 375.37 63 128.62 0.34 
4 3d H OCH3 OH C21H17N3O5 391.37 56 93.42 0.40 
5 3e H H N(CH3)2 C22H20N4O3 388.41 58 112.65 0.67 
6 3f H Cl H C20H14ClN3O3 379.79 62 89.24 0.72 
7 3g H OC2H5 OH C22H19N3O5 405.40 57 103.70 0.77 
8 3h OH H OH C20H15N3O5 377.35 43 143.34 0.75 
9 3i H OCH3 OCH3 C22H19N3O5 405.40 49 132 0.62 
10 3j H H F C20H14FN3O3 363.34 54 121 0.81 
3) Pyrazolyl  Benzoxazepine series (4a-j) 
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N
NCH3
N
O
O
O
R
2
R
3
R
1
 
4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-3-phenyl-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
Table 6: Physical characterization of Pyrazolyl Oxazepine  series (3a-j) 
SI no. 
Compd 
code 
R
1 
R
2 
R
3 
Molecular formula 
Molecular 
weight 
% Yield 
Melting 
point °C 
Rf  value 
1 4a H NO2 H C25H18N4O5 454.43 55 121 0.30 
2 4b H H Cl C24H16ClN3O3 429.85 43 119.62 0.52 
3 4c H H OCH3 C25H19N3O4 425.43 64 105 0.48 
4 4d H OCH3 OH C25H19N3O5 441.43 54 118.20 0.70 
5 4e H H N(CH3)2 C26H22N4O3 438.47 65 116.72 0.69 
6 4f H Cl H C24H16ClN3O3 429.85 43 132 0.33 
7 4g H OC2H5 OH C26H21N3O5 455.46 45 109.49 0.52 
8 4h OH H OH C24H17N3O5 427.40 56 117 0.39 
9 4i H OCH3 OCH3 C26H21N3O5 455.46 43 147 0.53 
10 4j H H F C25H18FN3O3 427.42 65 123 0.37 
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SPECTRAL CHARACTERIZATION OF COMPOUNDS
[94-96] 
The structures of synthesized compounds were established on the basis of 
the IR, UV, NMR, and Mass spectral data .
 
Compound code : 2a 
 
N
N
N
S
O
NO2
CH3  
 
Chemical name :  3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-
nitrophenyl)-1,3-thiazolidin-4-one 
UV Spectrum 
Solvent used :  Acetonitrile 
 λ max                            : 252.0 nm  
 IR (KBr, νmax in cm-1)  :  3487.63 (Aromatic, C-H), 1683.55 
(C=O,Thiazolidinone), 1596.77 (C=N), 1499.38 
(N=N), 1384.64(C-N),  821.527(Aromatic, C-H 
Bending), 755.95(C-S),  
1
HMR spectral data : 2.83 (s, 3H, CH3), 3.0 (s, 2H, Thiazolidinone), 5.20 
(s, 1H, CH-S), 6.8-7.92 (m, 9H, Ar-H), 8.29  
(s, 1H, Pyrazole) 
13
C NMRSPECTRA  : 35.59(CH3), 39.97 (C-S), 41.93 (C5 of 
Thiazolidinone), 42.63(C-N), 100.146(C=C, 
Pyrazole), 132.75-138.66 (Aromatic carbons), 
149.140 (C3, Pyrazole), 170.23 (C=O). 
Mass spectral data : 381.25 M+1 ion peak 
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UV spectrum 
 
IR Spectrum 
 
1
H NMR 
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C NMR
 
 
 
Mass Spectrum 
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Compound code : 2f 
N
N
N
S
O
CH3
Cl
 
Chemical name :  2-(2-chlorophenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one  
UV Spectrum 
Solvent used :  Acetonitrile 
 λ max                            : 252.0 nm  
 IR (KBr, νmax in cm-1) :  2921.83 (Aromatic C-H), 1683.55 (C=N), 
1596.77(C=O), 1498.42 (N=N), 1383.68 (C-N), 
1125.26 (N-N), 758.85(C-Cl), 617.10 (C-
S,Thiazolidinone). 
1
HMR spectral data : 2.25 (s, 3H, CH3), 3.31 (s, 2H, Thiazolidinone), 
5.64 ( s, 1H, CH-S), 7.14-7.53 ( m, 9H, Ar-H), 8.51 
(s, 1H, Pyrazole) 
13
C NMRSPECTRA  : 35.10 (C-Cl), 35.52(CH3), 39.97 (C-S), 41.98 (C5 of 
Thiazolidinone), 100.28 (C=C Pyrazole), 132.98-
137.080 (Aromatic carbons), 149.065 (C3, 
Pyrazole), 161.78 (C=O). 
Mass spectral data : 370.47 M+1 ion peak 
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UV Spectrum 
IR specturm 
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Mass spectrum 
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Compound code : 3a 
    
N
NN
O
O
O
C6H5
O2N
CH3
 
Chemical name :  3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-
nitrophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
UV Spectrum 
Solvent used :  Acetonitrile 
 λ max                                      : 251.0 nm  
 IR (KBr, νmax in cm-1)  :  3087.48(Aromatic,C-H), 1725.55 (C=O, 
Lactone),1616.06(Amide,C=O), 1596.77(C=N), 
1502.28(C=C), 1094,4 (N-N), 732.81 (Aromatic C-
H, bending) 
1
HMR spectral data : 3.5 (s, 3H, CH3),6.36-6.95 (d, 2H, Oxazepine), 
7.06-8.52 (m, 9H, Ar-H), 8.68 (s, 1H, Pyrazole), 
10.14 (s, 1H, Oxazepine) 
13
C NMRSPECTRA  : 39.29 (CH3), 60.52 (C7 of oxazepine), 128.58-
135.450 (Aromatic carbons), 147.95 (C3, Pyrazole), 
166.88 & 163.40 (C8 & C11 of oxazepine) 
Mass spectral data : 405.21 M+1 ion peak 
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UV Spectrum 
 
IR Spectrum 
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Mass Spectrum 
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Compound code: 3b 
 
N
NN
O
O
O
C6H5
Cl
CH3
 
 
 
Chemical name :  2-(4-chlorophenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
UV Spectrum 
Solvent used :  Acetonitrile 
 λ max                                      : 252.0 nm  
 IR (KBr, νmax in cm-1)  :  2922.59(Aromatic, C-H), 1725.98(C=O, Lactone), 
1625.7(C=O, amide, Oxazepine ring), 1595.81 
(C=N), 1089.58 (N-N), 695.212 (C-Cl). 
1
HMR spectral data : 3.56 (s, 3H, CH3), 6.23-6.36 (d, 2H, Oxazepine), 
6.96-8.33 (m, 9H, Ar-H), 8.35 (s, 1H, Pyrazole), 
10.34 (s, 1H, Oxazepine) 
13
C NMRSPECTRA  : 39.31 (CH3), 3 (C-Cl), 66.41 (C7 of oxazepine), 
128.58-135.450 (Aromatic carbons), 147.08 (C3, 
Pyrazole), 166.89 & 163.12 (C8 & C11 of 
oxazepine). 
Mass spectral data : 394.11 M+1 ion peak 
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UV Spectrum 
 
IR Spectrum 
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Mass spectrum 
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Compound code : 4a 
 
N
NN
O
O
O
C6H5
O2N
CH3
 
Chemical name :  3-(4-chlorophenyl)-4-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-
dione 
UV Spectrum 
Solvent used :  Acetonitrile 
 λ max                                  : 256.0 nm  
 IR (KBr, νmax in cm-1) :  3068.19 (Aromatic C-H, stretching), 1710.55 
(Lactone, C=O), 1614.13 (Amide, C=O), 
1596.77(C=N), 1578.45(Aromatic, C=C, Bending), 
1500.35 (C=C), 1350.89 (Aromatic Nitro grp), 
1093.44 (N-N). 
1
HMR spectral data : 2.50 (s, 3H, CH3), 7.2-8.07 (m, 13H, Ar-H), 8.32  
(s, 1H, Pyrazole), 13.26 (s, 1H, Oxazepine) 
13
C NMRSPECTRA  : 35.55 (CH3), 40.15(C-N), 68.37(C7 of oxazepine), 
100.186 (C=C, Pyrazole), 132.94-147.79 (Aromatic 
carbons), 148.35 (C3, Pyrazole), 168.72 & 163.42 
(C8 & C11 of oxazepine). 
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UV spectrum 
 
IR Spectrum 
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Compound code : 4j 
    
N
NN
O
O
O
C6H5
F
CH3
 
Chemical name :  3-(4-fluorophenyl)-4-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-
dione  
UV Spectrum 
Solvent used :  Acetonitrile 
 λ max                                      : 251.0 nm  
 IR (KBr, νmax in cm-1)  :  3060.48(Aromatic C-H), 1719.23 (C=O, Lactone), 
1598.7 (C=O, Amide), 1505.17(Aromatic, C=C), 
1228.43 (C-F), 1024.98 (N-N). 
1
HMR spectral data : 2.50 (s, 3H, CH3), 7.10-7.79 (m, 13H, Ar-H), 8.15 
(s, 1H, Pyrazole), 13.47(s, 1H, Oxazepine) 
13
C NMR SPECTRA  : 34.32 (C-F), 39.31 (CH3), 61.17(C7 of oxazepine), 
101.24 (C=C Pyrazole), 130.04-139.335 (Aromatic 
carbons), 147.91 (C3, Pyrazole), 168.69 & 163.17 
(C8 & C11 of oxazepine). 
Mass spectral data : 425.32 M-2 
 
ion peak 
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UV Spectrum 
 
IR Spectrum 
 
1
H NMR 
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5.3  PHASE III – BIOLOGICAL SCREENING 
5.3.1  In Vitro Antimalarial Screening
[97-102] 
 All the synthesized compounds were screened for antimalarial activity in 
the Microcare laboratory & TRC, Surat, Gujarat 
The in vitro antimalarial assay was carried out in 96 well microtitre 
plates according to the microassay protocol of Riekmann and co-workers with 
minor modification. The culture of P.falciparum strain were maintained in 
medium RPMI 1640 supplemented with 25mM HEPES, 1% D-glucose, 0.23% 
sodium bicarbonate and 10% heat inactivated human serum. The asynchronous 
parasites of P.falcipuram were synchronized after 5% D-sorbitol treatment to 
obtain only the ring stage parasitized cells. For carrying out the assay, an initial 
ring stage parasitaemia of 0.8 to 1.5% at 3% haematocrit in a total volume of 
200µl of medium RPMI-1640 was determined by Jaswant Singh Bhattacharya 
(JSB) staining to assess the percent of parasitaemia (rings) and uniformly 
maintained with 50% RBCs (O
+
). A stock solution of 5mg/ml of each of the test 
samples was prepared in DMSO and subsequent dilutions were prepared with 
culture medium. The diluted samples in 20µl volume were added to the test 
wells so as to obtain final concentration (at fivefold dilutions) ranging between 
0.4µg/ml to 100µg/ml in duplicate well containing parasitized cell preparation. 
The culture plates were incubated at 37°C in a candle jar. After 36 to 40 hours 
incubation, thin blood smears from each well were prepared and stained with 
JSB stain. The slides were microscopically observer to record maturation of 
ring stage parasites into trophozoites and schizonts in presence of different 
concentrations of the test agents. The test concentrations which inhibited the 
complete maturation into schizonts was recorded as the minimum inhibitory 
concentration (MIC). Chloroquine was used as the reference drug. 
 
Experimental Section 
 
 
 
 
 
Department of Pharmaceutical Chemistry 132 
RESULTS AND DISCUSSION 
 The in-vitro antimalarial assay results showed that the representative 
compounds exhibited antimalarial activity and the results are shown in Table 7. 
Table 7: In-vitro antimalarial assay 
Minimum Inhibitory Concentration (MIC) 
S.No Compound Name IC50 Mean Values
a
 
01 2g 0.95µg/ml 
02 3b 0.32µg/ml 
03 3h 1.41µg/ml 
04 4c 0.28µg/ml 
05 4j 1.07µg/ml 
06 Chloroquine 0.020µg/ml 
07 Quinine 0.268µg/ml 
a: means values in representative assay 
In the pyrazolyl thiazolidinone series, 2g (ethoxy) shows minimum 
inhibitory concentration at 0.95µg/ml. Among the pyrazolyl oxazepine series, 3b 
(chloro) had shown promising activity with the MIC of 0.32µg/ml and 3h 
(dihydroxy) showed MIC of 1.41µg/ml. Among the pyrazolyl benzoxazepine 
series, 4c (methoxy) had shown promising activity with the MIC of 0.28µg/ml 
and 4j (fluoro) showed MIC of 1.07µg/ml compared to standard chloroquine and 
quinine with the MIC of 0.02 and 0.26µg/ml. So, in the antimalarial screening for 
representative compounds, the chloro, methoxy and fluoro substituted derivatives 
of the three series showed significant activity.  
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5.3.2 Antibacterial Screening
[103,104]
 
Apparatus and chemicals required 
Sterile swab :  Hi-Media 
Non-adsorbent cotton :  Rama Raju Surgical Cotton Ltd. 
Conical flask  :  Borosil 
Test tubes :  Borosil 
Petri plates :  SD Fine-Chem Ltd 
Micropipettes  :  VARI Pipettes (Hi-Tab Lab) 
Autoclave :  Universal Autoclave 
Laminar Air Flow unit :  CLEAN Air Instrument Inc. 
Micro tips  :  Tarsons 
Agar powder  :  Hi Media 
 The antibacterial screening was carried out in the Pharmaceutical 
Biotechnology Laboratory, College of Pharmacy, SRIPMS, Coimbatore. 
Media used for antibacterial screening 
Muller Hinton Agar :  Hi-Media Laboratories Pvt. Ltd 
Ingredients  
Casein enzymatic hydrosylate :  17.5 gm/L 
Beef infusion :  300gm/L 
Soluble starch :  1.5gm/L 
Final pH at 25°C :  7.4 ±0.2 
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Screening For antibacterial activity   
All the newly synthesized compounds were screened for antibacterial 
activity by agar well diffusion technique.  
Preparation  
 The ingredients were dissolved in distilled water with the aid of heat and 
pH was adjusted to 7.2-7.6 using dilute alkali or acid. Sterilization 15 ml lots of 
Mueller Hinton agar were transferred to test tubes and the tubes were plugged 
with non-absorbent cotton. The test tubes were then autoclaved at a pressure of 15 
psi (120
o
C) for not less than 15 minutes.  
Culture used 
 Escherichia coli NCIM 2911 was procured from National Collection of 
Industrial microorganisms, Pune, Maharashtra and stored in the Pharmaceutical 
Biotechnology Laboratory, College of Pharmacy, Sri Ramakrishna Institute of 
Paramedical Sciences, Coimbatore – 641 044.  
Maintenance of culture  
The selected strains were confirmed for their purity and identity by Grams 
staining method and by their characteristic biochemical reactions. The selected 
strains were preserved by sub culturing them periodically on Nutrient agar slants 
and storing them under frozen condition. For the study, fresh 24 hrs broth cultures 
were used after standardization of the culture.  
Standardization of inoculum  
All the organisms were grown overnight (24 hours) at 37ᵒC on Nutrient 
agar and harvested during the stationary growth phase. Active cultures for 
experiments were prepared by transferring a loop full of cells from the stock 
cultures to test tubes containing Mueller-Hinton broth, incubated for 24 hrs at 
37ᵒC. Inoculum was standardized by matching the turbidity of the culture to 0.5 
McFarland standards. The standard was produced by mixing 0.5 ml of 0.048 M 
BaCl2 (1.175% w/v Barium Chloride dehydrate) with 99.5 ml of 0.36 N H2SO4. If 
the turbidity of the culture matches that of the McFarland standard, then the 
culture inoculating suspension has approximately 2.0 x 106 CFU/ml of bacteria.  
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Preparation of inoculums  
 The inoculum for the experiment was prepared fresh in Mueller Hinton 
Broth from preserved frozen slant culture. It was kept incubated at 37°C for 24 
hours. 
Drugs used  :  Newly Synthesized drugs (250µg/ml) 
Standard drugs :  ofloxacin (5µg/ml) 
Solvent  :  Dimethyl sulfoxide 
Agar well diffusion assay 
Mueller Hinton agar plates were prepared aseptically to get a thickness of 
5-6mm. The plates were allowed to solidify and inverted to prevent condensate 
falling on the agar surface. The plates were dried at 37°C before inoculation. The 
organisms were inoculated as per the following method in the plates prepared 
earlier. The sterile swab was dipped in the previously standardized inoculums and 
excess of inoculums was removed by pressing and rotating the swab firmly 
against the sides of the culture tube above the level of the liquid. The swab was 
then streaked all over the surface of the medium three times, rotating the plates 
through an angle of 60
o
 after each application. Finally, the swab was pressed 
round the edge of the agar surface. The inoculated medium was allowed to dry at 
room temperature, with the lid closed. Cork borer was sterilized by using flame 
and well was made by using cork borer. By using micropipette, the test sample 
and standard were added into the well and were refrigerated for one hour to 
facilitate uniform diffusion of the drug. This was then incubated for 18-24 hrs at 
37°C. The diameter of the zones of inhibition around the drugs were measured 
and compared with that of the standard. All the synthesized compounds were 
tested for antibacterial activity against Escherichia coli bacteria.  
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Table 8: Antibacterial data for 2a-j 
Sl no. Compound code Diameter of zone of inhibition in mm 
1 2a 11 
2 2b 12 
3 2c 13 
4 2d 12 
5 2f 13 
6 2e - 
7 2g - 
8 2h - 
9 2i - 
10 2j - 
11 3a 13 
12 3b 12 
13 3c 12 
14 3d 11 
15 3e 10 
16 3f 13 
17 3g 13 
18 3h 12 
19 3i 15 
20 3j 13 
21 4a 14 
22 4b 13 
23 4c 16 
24 4d 14 
25 4e 13 
26 4f 12 
27 4g 12 
28 4h 10 
29 4i 12 
30 4j 12 
31 Standard 32 
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Figure 8: Diameter of zone of inhibition 
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RESULTS AND DISCUSSION 
 All the newly synthesized compounds were tested for their antibacterial 
activity against Escherichia coli. Almost all the newly synthesized analogs were 
active against the tested microorganism at 250 µg/disc concentration by Kirby 
Bauer agar well diffusion method. It was observed that in the pyrazolyl 
thiazolidinone series derivatives, 2c (methoxy substitution) and 2f (chloro 
substitution) showed moderate sensitivity with a zone of 13 mm. Activity profile 
were compared to the standard ofloxacin (32mm). In the pyrazolyl oxazepine 
series compounds like 3a (nitro substituted), 3f (chloro substituted), 3i (methoxy 
substituted) and 3j (fluoro substituted) showed moderate sensitivity (13, 13, 15 
aand 13 mm) against Escherichia coli at 250 µg/disc concentration. Also in the 
pyrazolyl benzoxazepine, compound like 4a (nitro substituted), 4c (methoxy 
substituted) and 4d (3-methoxy-4-hydroxy substituted) showed moderate 
sensitivity with the zone of 14, 16 and 14 mm respectively. The data for zone of 
inhibition and the photographs are given in Table 8 and Figure10 respectively. 
Thus the biological screening reports suggested that the novel pyrazole 
linked thiazolidinone, oxazepine and benzoxazepine derivatives are promising in 
their antimalarial and antibacterial activity profile. Among the derivatives nitro, 
fluoro, chloro and methoxy derivatives were found to be significant.  
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SUMMARY AND CONCLUSION 
SUMMARY 
 The present work was focused on the design, docking, synthesis and 
evaluation of antimalarial and antibacterial activity of Pyrazolyl linked 
thiazolidinone, oxazepine and benzoxazepine series as possible Enoyl ACP 
reductase inhibitors. 
Phase I - In-silico studies 
 Selection of the target 
 The enzyme involved in the fatty acid elongation of Plasmodium 
falciparum and Escherichia coli ie., Enoyl ACP reductase was selected as the drug 
target of the study. The corresponding enzyme were obtained from the protein 
data bank and their accession codes were 1VRW (PfENR) and 1C14 (E.coli 
Fab1). 
 Selection of lead by virtual screening 
 Virtual screening was performed by iGEMDOCK v.2. Forty nine hits were 
obtained from ZINC database, from which pyrazole, thiazolidinone and oxazepine 
were selected as the lead for inhibiting PfENR and E.coli FabI enzymes. 
 Lead optimization 
 The thirty modified ligands 2a-j, 3a-j and 4a-j were subjected to in-silico 
lead optimization. The ligands were optimized for evaluating oral bioavailability 
by utilizing the Molinspiration server. Lead optimization revealed that all the 
thirty selected derivatives possess good drug likeness score. 
 Docking 
 The optimized leads were subjected to docking studies using Autodock4.2 
and the interactions of the derivatives with active sites of the enzymes were 
studied. The derivatives were subjected to interactions with PfENR and E.coli 
FabI. Triclosan was used as the standard ligand. 
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 Most of the derivatives were interacting with the key active sites of the 
PfENR (1VRW.pdb) with superior dock values or binding energies when 
compared to the standard (triclosan) with the binding energy of -5.28kcal/mol. 
Some of the derivatives though were interacting well with the enzymes, showed 
inferior binding energies predicting less binding affinity to the enzyme. Among 
the derivatives of pyrazolyl thiazolidinone, 2g, 2c and 2d (methoxy, chloro and 
ethoxy, methoxy and chloro) showed maximum binding energies -7.26, -6.59 and 
-6.43kcal/mol respectively. Also in pyrazolyl oxazepine derivatives, 3b, 3h and 
3a (chloro, dihydroxy and nitro) showed maximum binding energies of -9.51,        
-9.45 and -9.33kcal/mol respectively. Among the pyrazolyl  benzoxazepine  
derivatives, 4j, 4c, 4d and 4g (fluoro, methoxy, chloro and ethoxy) showed 
maximum binding energies of -9.19, -8.76, -8.43 and -7.58kcal/mol respectively. 
They were interacting well with key binding sites such as Tyr 267, Tyr 277, Met 
281, Gly313, Pro314 and NAD
+
.  
With the E.coli FabI (1C14.pdb) most of the derivatives were well 
interacting with the key active sites with excellent binding energies when 
compared to the standard (triclosan) with the binding energy of -7.15kcal/mol. 
Among the derivatives of pyrazolyl thiazolidinone derivatives, 2b, 2h and  
2a (chloro, dihydroxy, and nitro) showed maximum binding energies, -5.71, -5.69 
and -4.54 kcal/mol respectively. Also in pyrazolyl oxazepine derivatives, 3c,  
3d and 3j (chloro, methoxy and fluoro) showed maximum binding energies of -
7.58, -6.65 and -6.49kcal/mol respectively. Among the pyrazolyl benzoxazepine 
derivatives 4c, 4d, 4a and 4b (methoxy, 4-hydroxy-3-methoxy, nitro and chloro) 
showed maximum binding energies of -8.28, -8.24, -8.05 and -7.55kcal/mol 
respectively. They were interacting well with key residue such as Gly 93, Leu195, 
Tyr 158, Ala 196, Lle 200 and alse with NAD
+
.  
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Phase II - Synthesis 
Synthesis of 3-methyl-1-phenyl-1H-pyrazol-5-amine 
 An amount of β-aminocrotononitrile and phenylhydrazine hydrochloride 
was dissolved in dil.HCl and refluxed. The resulting reddish liquid was basified to 
alkaline pH with aqueous sodium hydroxide. The product obtained results in good 
yield. 
Synthesis of Schiff base (1a-j) 
 3-methyl-1-phenyl-1H-pyrazol-5-amine and benzaldehyde in presence of 
ethanol and few drops of glacial acetic acid were refluxed for 3 hours to form 
Schiff’s base. The product resulted in good yield. 
Synthesis of pyrazolyl thiazolidinone derivatives (2a-j) 
 Schiff’s base and mercaptoacetic acid (Thioglycolic acid) in presence of 
dioxan and anhydrous ZnCl2 was refluxed for 4hrs. After cooling, the resulting 
product was washed with sodium bicarbonate to remove unreacted thioglycollic 
acid to obtain series of pyrazolyl thiazolidinone in good yield.  
Synthesis of pyrazolyl oxazepine derivatives (3a-j) 
Schiff’s base and maleic anhydride in presence of hot dry benzene were 
refluxed. The solvent distilled off and the solid product obtained was in good 
yield. 
Synthesis of pyrazolyl benzoxazepine derivatives (4a-j) 
 Schiff’s base and phthalic anhydride in presence of hot dry benzene was 
refluxed and the solvent was distilled off to form the series of pyrazolyl 
benzoxazepine derivatives with good yield. 
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Characterization 
 Melting point of all newly synthesised compounds were determined. Rf 
values were determined by fixing various suitable solvent system on pre-coated 
silicagel-G plates. The solvent system used was ethyl acetate: n-Hexane (3:7).  
The structure was finally characterized by UV, IR, Mass, 
1
H and 
13
C NMR 
spectra. 
Phase-III - Biological activity 
 Antimalarial activity 
 The representative compounds from novel derivatives were screened for 
antimalarial activity was performed by in-vitro antimalarial assay technique by 
using Plasmodium falcipuram. In the pyrazolyl thiazolidinone series, 2g 
(ethoxy) showed minimum inhibitory concentration at 0.95µg/ml. Among the 
pyrazolyl oxazepine series, 3b (chloro) had shown promising activity with the 
MIC of 0.32µg/ml and 3h (dihydroxy) showed MIC of 1.41µg/ml. Among the 
pyrazolyl benzoxazepine series, 4c (methoxy) had shown promising activity with 
the MIC of 0.28µg/ml and 4j (fluoro) showed MIC of 1.07µg/ml compared to 
standard chloroquine and quinine with the MIC of 0.02 and 0.26µg/ml 
respectively. So, in the antimalarial screening for representative compounds, the 
chloro, methoxy and fluoro substituted derivatives of the three series showed 
significant activity. 
 Antibacterial activity 
 Antibacterial activity was performed by Kirby bauer disc diffusion method 
by using Escherichia coli NCIM2911. All the derivatives of three different series 
were screened for antibacterial activity. Among pyrazolyl thiazolidinone series, 
2b, 2c, 2d and 2f (chloro, methoxy, dimethoxy and o-chloro) had shown moderate 
sensitivity with a zone of inhibition 12, 13, 12 and 13 mm respectively. In the 
pyrazolyl oxazepine series, 3a, 3f, 3g and 3i (nitro, chloro, ethoxy and 
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dimethoxy) showed zone of inhibition 13, 13, 13 and 15mm respectively. Among 
the pyrazolyl benzoxazepine series, 4a, 4b, 4c, 4d and 4e (nitro, chloro, 
methoxy, dimethoxy and p-dimethyl amino) showed zone of inhibition 14, 13, 16, 
14 and 13 mm respectively. 
Thus in the pyrazolyl thiazolidinone series, ethoxy derivatives showed 
significant activity against the P. falcipuram and chloro, methoxy derivatives 
showed moderated sensitivity against the E.coli. In the pyrazolyl oxazepine 
series, chloro and dihydroxy showed promising activity against the P. falcipuram 
and dimethoxy derivatives showed moderate sensitivity against the E.coli. In the 
pyrazolyl benzoxazepine series, fluoro, methoxy derivatives showed activity 
against the organisms.   
Thus, the series of compounds synthesized can be utilized for anti-malarial 
and antibacterial activity by the mechanism of action of inhibition of Enoyl ACP 
Reductase enzyme. 
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CONCLUSION 
 The present study establishes that computational tools help in minimizing 
the tedious process of drug discovery and delivers new drug candidate 
more quickly.  
 Virtual screening was utilized for filtering the compounds and 
 selecting the lead compounds. 
 The drug likeness score established the compounds to be 
 pharmacokinetically active. 
 The binding energy obtained from docking study further confirmed the 
possibility of the affinity of the selected leads towards the enzyme, enoyl 
ACP reductase from Plasmodium falciparum and Escherichia coli. 
 Using the schemes various pyrazolyl linked thiazolidinone, oxazepine and 
benzoxazepine were synthesized with good yield. 
 Structure of the synthesized compounds were confirmed by Melting 
 point, TLC, UV, NMR and MASS spectra. 
 The compounds were screened for antimalarial and antibacterial 
 activity. 
Thus the present study depicts that the utilization of computer aided drug 
design is an efficient tool in predicting the effectiveness of a series of compounds 
under study and thus can result in the design of potent antimalarial and 
antibacterial agents.  
FUTURE PERSPECTIVE 
As the extension of the research project the series of pyrazolyl linked 
thiazolidinone, oxazepine and benzoxazepine can be subjected to PfENR and 
E.coli FabI enzyme inhibitory studies.  
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OUT COME OF THE STUDY 
 From the present study, the most significant compound were found to be 
N
N
N
S
O
CH3
Cl
 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(2-chlorophenyl)-1,3-thiazolidin-4-one 
N
NN
O
O
O
C6H5
Cl
CH3
 
2-(4-chlorophenyl)-3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2,3-dihydro-1,3-
oxazepine-4,7-dione 
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N
NN
O
O
O
C6H5
O2N
CH3
 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-nitrophenyl)-2,3-dihydro-1,3-
oxazepine-4,7-dione 
N
NN
O
O
O
C6H5
F
CH3
 
3-(4-fluorophenyl)-4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-3,4-dihydro-2,4-
benzoxazepine-1,5-dione 
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LIST OF NEWLY SYNTHESIZED COMPOUNDS 
SERIES-1 
N
N
N
S
O
CH3
R
 
Compd 
code 
R Compound Name 
2a 3-NO2 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-
nitrophenyl)-1,3-thiazolidin-4-one 
2b 4-Cl 
2-(4-chlorophenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one 
2c 4-OCH3 
2-(4-methoxyphenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one 
2d 3-OCH3,4-OH 
2-(4-hydroxy-3-methoxyphenyl)-3-(3-methyl-1-
phenyl-1H-pyrazol-5-yl)-1,3-thiazolidin-4-one 
2e 4-N(CH3)2 
2-[4-(dimethylamino)phenyl]-3-(3-methyl-1-
phenyl-1H-pyrazol-5-yl)-1,3-thiazolidin-4-one 
2f 2-Cl 
2-(2-chlorophenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one 
2g 3-OC2H5,4-OH 
2-(3-ethoxy-4-hydroxyphenyl)-3-(3-methyl-1-
phenyl-1H-pyrazol-5-yl)-1,3-thiazolidin-4-one 
2h 2,4-OH 
2-(2,4-dihydroxyphenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one 
2i 3,4-OCH3 
2-(3,4-dimethoxyphenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one 
2j 4-F 
2-(4-fluorophenyl)-3-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-1,3-thiazolidin-4-one 
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SERIES-2 
N
NN
O
O
O
C6H5
CH3
R
 
Compd 
code 
R Compound Name 
3a 3-NO2 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-
nitrophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
3b 4-Cl 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(4-
chlorophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
3c 4-OCH3 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(4-
methoxyphenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
3d 3-OCH3,4-OH 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(4-
hydroxy3-methoxy phenyl)-2,3-dihydro-1,3-oxazepine-
4,7-dione 
3e 4-N(CH3)2 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-
(dimethiamino)phenyl)-2,3-dihydro-1,3-oxazepine-4,7-
dione 
3f 2-Cl 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(2-
chlorophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
3g 3-OC2H5,4-OH 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3-ethoxy-4-
hydroxyphenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
3h 2,4-OH 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(2,4-
dihydroxyphenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
3i 3,4-OCH3 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(3,4-
dimethoxyphenyl)-2,3-dihydro-1,3-oxazepine-4,7-
dione 
3j 4-F 
3-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-(4-
fluorophenyl)-2,3-dihydro-1,3-oxazepine-4,7-dione 
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SERIES -3 
N
NN
O
O
O
C6H5
CH3
R
 
 
Compd 
code 
R Compound Name 
4a 3-NO2 
3-(4-chlorophenyl)-4-(3-methyl-1-phenyl-1H-pyrazol-
5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4b 4-Cl 
3-(4-chlorophenyl)-4-(3-methyl-1-phenyl-1H-pyrazol-
5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4c 4-OCH3 
3-(4-methoxyphenyl)-4-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4d 
3-OCH3,4-
OH 
3-(4-hydroxy3-methoxyphenyl)-4-(3-methyl-1-phenyl-
1H-pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-
dione 
4e 4-N(CH3)2 
3-(3-(dimethiamino)phenyl)-4-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4f 2-Cl 
3-(2-chlorophenyl)-4-(3-methyl-1-phenyl-1H-pyrazol-
5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4g 
3-OC2H5,4-
OH 
3-(3-ethoxy-4-hydroxyphenyl)-4-(3-methyl-1-phenyl-
1H-pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-
dione 
4h 2,4-OH 
3-(2,4-dihydroxyphenyl)-4-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4i 3,4-OCH3 
3-(3,4-dimethoxyphenyl)-4-(3-methyl-1-phenyl-1H-
pyrazol-5-yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
4j 4-F 
3-(4-florophenyl)-4-(3-methyl-1-phenyl-1H-pyrazol-5-
yl)-3,4-dihydro-2,4-benzoxazepine-1,5-dione 
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